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Abstract 
Corticosteroids represent an important class of compounds that are used to control 
cisplatin-induced acute and delayed emesis in man. There are also reports that 
corticosteroids can antagonise motion-induced emesis. 
A behavioural and neurochemical approach was used to investigate the anti-emetic 
mechanism of action of several corticosteroids in the ferret and Suncus murinus 
It 
(house musk shrew). Cisplatin (5 mg/kg, i.p.) induced an acute and delayed emetic 
response in the ferret. Several glucocorticoids were used and the rank order of anti-
emetic potency (betamethasone > dexamethasone > methylprednisolone > 
hydrocortisone) to reduce emesis indicated an involvement of glucocorticoid � 
receptors and the involvement of inflammation or inflammatory mediators. The 
most glucocorticoid sensitive phase of the response was seen 24-56 h post cisplatin 
injection but the process of inflammation probably occurred earlier on day 1. Emesis 
occurring after 56 h was sensitive to fludrocortisone indicating an involvement of 
mineralocorticoid receptors. The non-selective cycloxygenase (COX) inhibitor, 
indomethacin, but not the cycloxygenase-2 selective inhibitors, DFU or L-745,337, 
potentiated delayed emesis to suggest a protective role of cycloxygenase-1 against 
the actions of cisplatin. Conversely, the anti-emetic action of DFU suggests that 
prostanoids and cycloxygenase-2 may be involved in delayed emesis but the results 
were not supported by the action of L-745,337. Further, the action of the 
glucocorticoids was not mimicked by the combination treatment of indomethacin 
with the 5-lipoxygenase inhibitor, MK-886, indicating that cisplatin induces delayed 
emesis via mechanisms other than, or in addition to, production of prostanoids and 
iii 
leukotrienes. MK-886 also failed to antagonise emesis as a single treatment. 
Cortrosyn (ACTH 1-24) was effective in antagonising acute and delayed emesis via 
an unknown mechanism but the cortisol inhibitor, metyrapone, failed to potentiate 
the delayed emetic response. 
Motion induced a retching and vomiting response in Suncus murinus that was not 
reliably antagonised by dexamethasone and was resistant to treatment with 
betamethasone and methylprednisolone. However, motion induced elevations in the 
1» 
levels of cortisol were reduced by treatment with glucocorticoids. Conversely, none 
of the glucocorticoids affected the levels o fACTH or cortisol in normal animals. 
It is concluded that corticosteroids antagonise cisplatin-induced emesis in the ferret � 
probably via a mechanism involving glucocorticoid receptors and possibly by 
mediators other than, or in addition to, prostanoids and leukotri^es. The motion-
induced emesis model in Suncus murinus is not reliable for dissecting the anti-emetic 







個皮質類固醇止嘔程度排列順序如下betamethasone ^ dexamethasone > 
It 
methylprednisolone > hydrocortisone ^此結果表明止驅作用涉及糖皮質類固醇 
(glucocorticoid)感受器，炎症或炎症介質。糖皮質類固醇拮抗金屬鉑引致嘔 








酶（ l ipoxygenase)抑制劑MK-8^未顯示拮抗金屬鉑的致吐作用，但鉑引起 
的遲發性幅吐仍然可能通過其它產物的機制或/及前列環素和leukotrienes，單 
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1.1.1 Chemical Structure of Steroids 
Corticosteroids are classified into two types - (a) glucocorticoids (the 17-
hydroxylated corticosteroids) and (b) mineralocorticoids (the 17-
deoxycorticosteroids). The basic steroidal structure has four fused hydrocarbon rings 
that form the basic molecular skeleton. The nomenclature used to name carbon atoms 
of the steroids follows an international system and is shown in Figure 1.1.1 
!• 
ff 
Fig 1.1.1 Basic steroid molecular skeleton 
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1.1.2 Biosynthesis of Endogenous Corticosteroids 
The precursor used in the synthesis of mammalian corticosteroids is cholesterol. 
Figure 1.1.2 shows a simplified biosynthesis pathway. The pathway utilises five P450 
cytochromes: cholesterol desmolase (P450 scc), 17a-hydroxylase (P450 cl7), 3p-
hydroxysteroid dehydrogenase, 2ip-hydroxylase (P450 c21) and 11 P-hydroxylase 
(P450 c l l ) . P450 SCC and P450 c l l are located in mitochondria and the other three 
cytochromes are located in the smooth endoplasmic reticulum (Ganong, 1997). The 
endogenous corticosteroids, including glucocorticoids and mineralocorticoids are 
formed in the adrenal cortex. 
3 
Figure 1.1:2 Pathway of steroid biosynthesis in the adrenal cortex 
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1.1.2.1 Regulation of cortisol synthesis and negative feedback system 
•* 
Corticotrophin-releasing hormone (CRH) is important in regulating corticosteroid 
synthesis. It is a hormone released from the hypothalamus and stimulates the release 
of adrenocorticotrophin (ACTH) from the anterior pituitary and thus stimulates the 
adrenal cortex to secrete corticosteroids, mairdy glucocorticoids (Gottfried, 1994; 
Kangetal., 1995). 
ACTH secretion is inhibited by endogenous and exogenous corticosteroids through 
both rapid and delayed feedback mechanisms. Both types of feedback operate at the 
level at the pituitary by inhibiting the response to CRH or, at the hypothalamus by 
inhibiting the secretion of CRH. ACTH also inhibits CRH release by a short-loop 
4 
feedback mechanism (Frohman, 1996b). The regulation of corticosteroid synthesis 
and the sites of negative feedback are shown in Figure 1.1.3. 
Figure 1.1.3 Regulation of synthesis and secretion of adrenal corticosteroid (+, 
stimulates; -, inhibits) 
— • Hypothalamus ^ — 
CRH •‘ 
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Glucocorticoids can act on at least two functionally different receptor systems within 
the brain. There are the mineralocorticoid (type I) receptors and the glucocorticoid 
(type II) receptors (Dallman et al., 1989). In addition, a type III receptor has been 
suggested to exist in the kidney but its physiological function has not been 
determined (Feldman et al., 1973; Naray-Fejes-Toth et al., 1994). 
1.1.3 Biological Significance of Corticosteroids 
In general, endogenous glucocorticoids play a role in glucose metabolism and the 
regulation of the immune system whereas mineralocorticoids are important in 
maintaining fluid and electrolyte homeostasis (Gottfried, 1994). 
5 
Endogenous glucocorticoids are well known to have an effect on metabolism. The 
overall effects on carbohydrate and protein metabolism result in an increase in 
glucose production. The glucose can then enter the bloodstream and is transported to 
the cells where it is used for energy. This may be important in situations where the 
body reacts to stress (Gottfried, 1994). The glucose changes are accomplished by the 
induction of many glycolytic enzymes and aminotransferases Q^adarro, 1964). The 
actions of glucocorticoids that affect carbohydrate metabolism involve an increased 
protein catabolism in the periphery, resulting in an increase in the concentration of 
It 
amino acids in plasma. , 
1.1.3.1 Involvement of corticosteroids as anti-inflammatory drugs 
Corticosteroids are important drugs that inhibit inflammation (Nadarro, 1964). The 
anti-inflammatory action of glucocorticoids may act in part by inhibiting eicosanoid 
synthesis through regulation of phospholipase A2, which is required for the 
generation of arachidonic acid. However, the biochemical mechanism of action is 
perhaps more complicated. Glucocorticoid action may involve the induction of the 
expression of lipocortin, a polypeptide with phospholipase A2 (PLA2) inhibitory 
properties. However, there is not sufficient evidence to prove that lipocortins are 
direct regulators of phospholipase A2 (Davidson & Dennis, 1989) and they may not 
be the essential mediators of glucocorticoid-induced inhibition of phospholipase A2 
(Goppelt-Struebe, 1997). 
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1.1.3.2 Eicosanoid biosynthesis 
Products derived from the metabolism of arachidonic acid (AA) (5,8,11,14-
eicosatetraenoic acid) affect a variety of biological processes and hold a central role 
in the inflammation process. These products are termed eicosanoids (Greek eicosi = 
20). 
Arachidonic acid is a 20-carbon polyunsaturated fatty acid with 4 Rouble bonds and 
is derived primarily from dietary linoleic acid. The major source in the body is an 
esterified form which is a component of most cell membrane phospholipids. Many 
stimuli such as mechanical, chemical and physical stimuli can activate the release of 
arachidonic acid. Free arachidonic acid is released from the phospholipids by a � 
phospholipase enzyme, primarily cPLA2, which is contained in lysosomes. 
•* 
Inflammation is also associated with its activation via the inflammatory mediator, 
anaphylatoxin C5a (Mitchell & Warner, 1999). 
Eicosanoids comprise three main biologically active classes of arachidonic acid 
metabolites: (1) prostaglandins (PG) and thromboxanes (Tx); (2) leukotrienes (LT), 
lipoxins and hydroxyeicosatetraenoic acids (HETE), and (3) epoxyeicosatraenoic 
acids (EET) which are produced by the following corresponding enzymes: 
cycloxygenase (COX), lipoxygenase (LOX) and cytochrome-P450 (Grossman et al., 
1997) (see Figure 1.1.4). 
7 
Figure 1.1.4 Biosynthesis of arachidonic acid metabolites and sites at which 
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1.1.3.2.1 Cycloxygenase pathway — 
It is now known that at least two isoforms of cycloxygenase exist (Guiliano & 
Warner, 1999) - constitutive cycloxygenase-1 (C0X-1) and inducible 
cycloxygenase-2 (COX-2). Large amounts of inducible cycloxygenase-2 are 
produced during an inflammation (Mitchell & Warner, 1999). Both isoforms 
catalyse the formation of prostaglandin G2 followed by prostaglandin H2 from 
arachidonic acid. Further products of this pathway include PGE2, PGD2, PGF2a, 
PGI2 and thromboxane k : . Upon appropriate stimulation, like bacterial infection, 
several prostaglandins are synthesised, utilised, and metabolised in situ. 
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1.1.3.3 Lipoxygenase pathway 
5-Lipoxygenase is the predominant arachidonic acid-metabolising enzyme in 
neutrophils. It converts arachidonic acid into 5-hydroperoxy-eicosatetraenoic acid 
(5-HPETE), resulting in the formation of 5-hydroxyeicosatetraenoic acid (5-HETE), 
which is chemotactic for neutrophils. 5-HPETE may also generate leukotriene A4 
(LTA4), which in turn may be hydrolysed to generate leukotriene B4 (LTB4). 
Leukotriene B4 can cause potent chemotaxis and aggregatio^ of neutrophils. 
Alternatively, by the addition of glutathione, leukotriene A4 (LTA4) can give rise to 
leukotriene C4 (LTC4) which can be further metabolised to leukotriene D4 (LTD4) 
and leukotriene E4 (LTE4). These compounds cause vasoconstriction, bronchospasm 
and increased vascular permeability (Rang et al., 1995). � 
1.1.3.4 Side-effects of prolonged use ofcorticosteroids 
A single administration of a corticosteroid is not normally associated with severe 
adverse effects (Fauser et al., 1999; Splinter & Roberts, 1996). However, the 
potential side-effects of multiple doses of corticosteroids include fluid retention, 
alternations in electrolyte balance, sweating and glucose intolerance (Zaglama et al., 
1986). Other common effects also include mood changes (Mitchell & 0'Keane, 
1991)，increased energy levels, insomnia, euphoria and anxiety (Cassileth et al., 
1983; Cassileth et al., 1984). Patients may also develop gastrointestinal 
complications and diabetes, perineal burning (Allan & Leonard，1986) or pruritis, 
somnolence and drowsiness (Zaglama et al., 1986). Headache, metallic taste, 
9 
abdominal discomfort, itchy throat, and a swollen feeling in the mouth have also 
been reported (Cersosimo & Karp, 1986; Fauser et al., 1999). 
Adrenal suppression may occur following long term therapy with corticosteroids 
(Saglama et al., 1986). The ability of the pituitary gland to secrete ACTH may be 
impaired, resulting in a poor response to medical or surgical stress. In the long term, 









1.2.1 Motor Path way of Emetic Reflex 
The emetic reflex is envisaged to have evolved as a protective defence mechanism 
against the potential absorption of toxic substances from the gastrointestinal tract 
(Borison & Wang, 1953). 
1.2.1.1 Retching and vomiting 
t% 
ff 
The emetic reflex is associated with retching and vomiting. Retching usually 
precedes or accompanies vomiting (Borison & Wang, 1953). Gastric motility slows 
or ceases and retroperistalsis may occur during periods of nausea and vomiting � 
(Akwari, 1983). 
The act of vomiting is mediated by both somatic and autonomic processes. It is 
performed by the same set of muscles involved in normal respiration and generates 
necessary forces on the stomach to evacuate the gut. To achieve this, there is co-
ordinated respiratory pumping pressure patterns in the thorax and abdomen (McCarty 
&Borison,1974). 
1.2.1.1.1 Physiological studies 
Retching results from the raised intra-abdominal pressure but lowered intra-thoracic 
pressure, whereas, in vomiting, both intra-abdominal and intra-thoracic pressures 
become positive (Andrews et al., 1996). There is contraction of diaphragm and 
12 
abdominal muscles to increase the intragastric pressure. At the same time, the 
cardiac sphincter at the lower end of the oesophagus relaxes. Forceful contractions 
of the rectus abdominis and external oblique muscles raise intra-abdominal pressure, 
but lower intra-thoracic pressure. The positive abdominal pressure is transferred to 
the thorax and thus causes vomiting (Borison & McCarthy, 1983; Leslie, 1986). 
There are certain similarities and relationships between the activities of the vomiting 
and the respiratory centres (Borison & Wang, 1953). Borison and Wang (Borison & 
Wang, 1949) showed that both centres are located in close mutual proximity in the 
reticular formation. Some regions involved in the generation of the breathing rhythm 
are involved in the emetic reflex system. They include the dorsal respiratory group 
located in the ventrolateral subnucleus of the nucleus tractus solitarius, a ventral � 
respiratory group comprising neurons located in the region of the nucleus ambiguus, 
including the nucleus retroambigualis and the Botzinger complex (Andrews & Davis, 
1995). 
1.2.1.2 Nausea 
Nausea is a psychological experience which may or may not be associated with 
vomiting (Borison & Wang, 1953). However, if vomiting occurs, it is usually the 
feeling that precedes vomiting. It is accompanied by autonomic changes that include 
decreased gastric and pyloric tone and duodenal-gastric reflux. 
Nausea may be associated with pallor and tachycardia in humans (Bumette & 
Perkins, 1992; Feldman et al., 1988; Verbalis et aL, 1987) and possibly behavioural 
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changes in animals such as licking, backwards walking and posturing (Bermudez et 
al., 1988; Matsuki et al., 1997). However, no direct measurement can be made using 
animal models. In some circumstances such as space motion sickness or intestinal 
obstruction, sudden vomiting may occur in the absence of nausea (Lackner & 
Graybiel, 1986; Thornton et al., 1987a; Thornton et al., 1987b). 
1,2.2 Components of the Emetic Reflex 
i> 
产 
The important components of the reflex include the gastrointestinal tract (pharynx, 
stomach, duodenum), higher cortical and limbic regions of the forebrain and 
supramedullary (labyrinth, diencephalon) and medullary structures (area postrema, 
% 
nucleus tractus solitarius, vestibular complex) of the hindbrain. The key components 
of the emetic reflex are the ‘vomiting centre，(VC), the chemoreceptor trigger zone 
(CTZ) in the area postrema (AP) and the nucleus tractus solitarius Q^TS) 
(Mitchelson, 1992a; Naylor & Rudd, 1994). 
In general, the vomiting centre receives input from numerous sources and sets off a 
chain of nerve impulses to initiate the reflex. Other components relay information to 
the vomiting centre (Wang & Borison，1950) and their degree of involvement are 
different between emetic agents and species (Andrews et al, 1988; King, 1990). For 
example, toxins in blood or cerebrospinal fluid activate the chemoreceptor trigger 
zone, which increases the efferent activity of the vomiting centre. Agents like 
staphylococcal enterotoxin, oral copper sulphate (CuSO4) probably stimulate the 
activity of vomiting centre via visceral afferents. Other agents like apomorphine, 
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mechlorethamine and 5-fluorouracil require the intact chemoreceptor trigger zone to 
induce emesis (Maule & Perry, 1983). 
L2.2.1 The vomiting centre (VC) 
Several studies were performed in the early 1900's to identify the location of the 
vomiting centre (Borison & Wang, 1953). However, the concept of the vomiting 
centre was based on studies by Borison and Wang in 1949 (Borison & Wang, 1949) 
/f 
who showed that vomiting could be produced by electrical stimulation of a region of 
the brainstem of unanesthesised, decerebrated cats. They suggested that the location 
was situated in the dorsal portion of the lateral reticular formation. On the basis of 
% 
additional experiments, Borison and Wang postulated the existence of chemoreceptor 
trigger zone (located in the area postrema) on the surface of medulla and that the 
vomiting centre itself is not sensitive to emetic agents. It serves solely to co-ordinate 
the reflex process that the emetic detection sites input into it (Borison et al., 1984; 
Borison & Wang, 1953). Recent studies have concluded that a discrete vomiting 
centre dose not exist but rather represents a collection of effector nuclei in the 
brainstem area (Andrews & Hawthom，1988; Lawes, 1991). 
1.2.2.2 Area postrema (AP) / Chemoreceptor trigger zone (CTZ) 
The area postrema is a highly vascularised circumventricular organ located outside 
the blood brain barriers and cerebrospinal fluid (CSF)-brain barriers. The brain area 
is therefore ideally suited for the detection of systemic emetic agents. Adrenaline 
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and dopamine, for instance, can directly influence area postrema neurons to induce 
emesis (Andrews et al., 1988). 
The area postrema is found in all mammalian species and many other vertebrate 
species (Borison, 1974). It is situated at the caudal extremity of the fourth ventricle. 
The name of area postrema was conferred by Retzius in 1896. However, it was not 
until 1960 that its identity became firmly established as being involved in the emetic 
reflex (Borison, 1984). 
II 
The area postrema acts mainly as the chemoreceptor trigger zone for emetic response 
although it is involved in other functions (Borison, 1974; Leslie, 1986) (see below). 
It serves as a specialised chemosensitive region for triggering emetic reflex by � 
certain central emetic agents (Borison & Brizzee, 1951; Borison & Wang, 1953). 
However, the exact role of how the area postrema acts as a chemoreceptor is not 
known (Andrews et al., 1988). 
Apart from a role in emesis, the area postrema is implicated in other physiological 
processes. These include the regulation of blood pressure (Barnes et al., 1984; 
Miceli et a/., ' l987), sleep (Leslie, 1986), food intake (both normal and that modified 
by cancer) (Borison, 1974; Miceli et aL, 1987)，conditioned taste aversion (Rudd et 
al., 1998), respiration (Borison, 1974; Leslie, 1986; Miceli et al., 1987), renal 
function (Borison, 1974; Leslie, 1986) and choroid plexus function (Leslie, 1986). 
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1.2.2.3 The nucleus tractus solitarius (NTS) 
The nucleus tractus solitarius lies below the area postrema in the floor of the fourth 
ventricle and is also a main site involved in emesis fNaylor & Rudd, 1994). The area 
postrema also receives vagal afferent input and has neurons extending into nucleus 
tractus solitarius (Yuan & Rarber, 1993). Inputs from the fauces also run to the 
nucleus tractus solitarius and then to the vomiting centre (Mitchelson, 1992a). 
I* 
1.2.2.4 Gastrointestinal tract and vagus nerves 
There are four origins of vagus nerve from the brain stem including the dorsal motor 
% 
nucleus of vagus, the nucleus ambiguus, the nucleus tractus solitarius and the sensory 
nucleus of trigeminal nerve (Thibodeau, 1996). The nucleus tractus solitarius is the 
site at which many vagal afferents terminate. Neuroanatomical tracing studies have 
demonstrated the area postrema receives vagal efferents from the vagus nerve 
(Leslie, 1986; Leslie & Gwyn，1984; Miceli et al., 1987; Yuan & Rarber, 1993). 
Electrical stimulation of the vagus is known to elicit emesis in the cat and other 
species (Fukui et al., 1993a). 
Emesis may also be triggered by impulses transmitted through nervous pathways 
either from the stomach or the intestine. Ingested toxins such as copper sulphate, 
ipecacuanha and gastric irritation activate afferent axons via gastrointestinal 
receptors. They include the chemoreceptors located in the wall of the upper gut, 
mechanoreceptors, and possibly receptors in hepatic portal vein (Andrews & 
Hawthorn, 1988). The activated receptors relay information via the vagus nerves. 
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The splanchnic nerves also play a role in relaying information from the 
gastrointestinal tract (Grundy & Reid，1994). 
1.2.2.5 Neurotransmitter receptors 
Some receptor antagonists have anti-emetic actions (see below). In addition, 
administration of some receptor agonists such as morphine (an opiod-receptor 
agonist) can induce emesis. The emetic reflex consists of detector sites and outputs. 
The detector sites identify the emetic stimuli and transmit impulses to the vomiting 
fT 
centre through afferents. Neurotransmitter receptors associated with nausea and 
vomiting are located peripherally and centrally in the brain (Cubeddu, 1992). 5-
hydr0xytryptamine3 (5-HT3) receptor binding sites have been reported peripherally, 
、 
in the gastrointestinal tract, on vagal afferents and centrally in the dorsal nucleus of 
the vagus nerve, the nucleus tractus solitarius and area postrema (Ettinger, 1995; 
Naylor & Rudd, 1996). a2-Adren0cept0rs, dopamine D2 receptors, histamine Hi and 
H2 receptors, muscarinic Mi receptors, nicotinic receptors and opioid ^- and 6-
receptors are also located within the area postrema (Beleslin, 1992). Muscarinic 
receptors are also located in the vestibular apparatus, in afferents at vestibular 
nucleus and in other brain stem areas. Further, some neuroactive compounds, when 
applied iontophoretically, show excitatory effects on neurons of area postrema. 
These include noradrenaline, 5-HT, neurotension, leu-enkephalin, vasoactive 
intestinal polypeptide, substance P (SP), glutamate, histamine, dopamine, 
apomorphine, angiotensin II, thyrotropin-releasing hormone, gastrin and vasopressin 
(Grundy & Reid, 1994; Leslie, 1986). 
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1.3.1 Cancer as a cause of mortality in Man 
Cancer is a disease that arises from an uncontrolled or abnormal division of cells that 
can invade and destroy the surrounding tissues. In Hong Kong, cancer accounts for 
over 9,000 deaths per year, which reflects 30 % of all mortality in the region 
(Reported from the Hong Kong Anti-Cancer Society, 1998). It is also a major cause 
of mortality around the world. Approximately 18,000 new cases of cancer are 
1« 
diagnosed annually in Hong Kong (Reported by The Hong Kong Anti-Cancer 
A 
Society, 1998). Malignant neoplasms of trachea, bronchus and lung are the main 
cause of death from cancer in Hong Kong (Reported by Department of Health 1988-
1997). Chemotherapy is a treatment for cancer but there are other treatments like 
、 
surgery, radiotherapy, endocrinotherapy and immunotherapy. (Cain & Tenni，1992; 
C a l m m e t a l . , 1980). „ 
1.3.2 Chemotherapeutic Agents 
Chemotherapy involves the use of cytotoxic medications and chemicals to kill the 
cancer cells. Most agents affect either macromolecular synthesis or function, 
interfering with either the synthesis ofDNA, RNA, or proteins. 
1.3.2.1 Different classes 
Anti-cancer drugs have been classified according to their action to disrupt cell 
growth. They have been divided mainly into 6 groups and examples are shown in 
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Table 1.3.1: antimetabolites, alkylating agents, antibiotics, plant alkaloids, hormonal 
agents and miscellaneous synthetic drugs (Britain, March 2000b; Carter et al., 1997). 
Most drugs seem to fit into one or more category. The classification scheme is 
helpful in the rational selection of agents for the treatment of different causes of 
cancer. 
Fig 1.3.1 Examples of anti-cancer drugs 
Antimetabolites Alkylating Antibiotics Plant Alkaloids Hormonal Miscellaneous 
II 
Agents Agents Synthetic 
5-Fluorouracil Busulfan Actinomycin D Doxorubicin Calusterone Cisplatin 
Procarbazine Carmustine Daunorubicin Mitomycin Dexamethasone Dacarbazine 
Thioguanine Chlorambucil Doxorubicin Vinblastine Prednisolone Procarbazine 
Cyclo- Mitomycin C Vincristine Nafoxidine 
phosphamide 
Dacarbazine � 
Cisplatin belongs to the miscellaneous synthetic group. It is non-specific and is most 
active in the Gi sub-phase of the cell cycle. It is an inorganic drug containing 
platinum and chlorine atoms. It binds to DNA and acts like alkylating agents by 
forming intrastrand DNA crosslinks. This action prevents cell replication and is the 
mechanism to kill the cancer cells. 
1.3.2.2 Emetogenic potential 
Nausea and vomiting experienced by cancer patients may be related to cancer itself 
(Goodman, 1997), chemotherapy, and other medications not associated with 
chemotherapy including pain medications, long-acting bronchodilators and 
antibiotics (Gralla, 1993). Despite the emergence and widespread use of more 
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effective anti-emetic agents, nausea and vomiting remains problematic and affects 
the quality of life in 40-50% of patients who receive chemotherapy (Goodman, 
1997). In some circumstances, where patients require combination therapy, an 
individual may receive more than one drug with a potential to cause significant 
nausea and vomiting (Goodman, 1997). 
There are wide differences in the emetogenic potential of cytotoxic drugs. This type 
of categorisation is useful in deciding the anti-emetic regimen. The frequency of 
it 
nausea and vomiting ranges from very,low (<10%) to very high (>90%) (see Table 
1.3.2 for examples of drugs). It is generally accepted that cisplatin is the most 
emetogenic of the chemotherapeutic agents (Cersosimo & Karp, 1986). On the other 
hand, agents like busulfan and vincristine rarely produce emesis. � 
Emesis is also dose-dependent. For instance, low-dose of methotrexate seldom 
produces severe side-effects but in high-dose regimens, it causes severe vomiting. 
Other agents such as cisplatin, ifosfamide, cyclophosphamide and cytarabine also 
have dose-dependent emetogenicity (Goodman, 1997). 
Apart from the emetic intensity, the emetic onset and duration also vary for different 
drugs. It has been suggested that there is a correlation between the onset of emesis 
and the emetogenic potential of chemotherapeutic agents (Ettinger, 1995). However, 
there is no clear evidence to support the correlation between these three factors. 
Most drugs are emetogenic for approximately 12-24 h after administration (Ettinger, 
1995) but cisplatin, cyclophosphamide and mitomycin have a duration greater than 
72 h (Tavorath & Hesketh, 1996). Other factors that influence the frequency and 
‘ 22 
severity of emesis are the patient characteristics, such as the circadian cycle, age, 
gender, alcoholic intake history and prior chemotherapy (Audhuy et al., 1996; 
Goodman, 1997; Pollem&Giannarell, 1989). 
Table 1.3.2 Examples of cytotoxic drugs grouped according to the emetogenic 
potential (table based on the information from (Borison & McCarthy, 1983; 
Goodman, 1997; Hesketh et al., 1997; Markham & Sorkin, 1993; Skeel & Lachant, 
1995; Tortorice & OiConnell, 1990)) 
I* 
产 
Very high High Moderate Low Very low 
>90 % 60-90 % 30-60 % 10-30% <10% 
Cisplatin Cyclo- Asparaginase Bleomycin Busulfan 
Chlormethine phosphamide Daunorubicin Cytarabine Chlorambucil 
Dacarbazine Actinomycin D Doxorubicin Etoposide 6-Thioguanine � 
Streptozotocin Lomustine 5-Fluorouracil Ifosfamide Vinblastine 
Plicamycin Mitomycin-C Methotrexate Vincristine 
Procarbazine 
1.3.3 Cisplatin-Induced Emesis 
The use of anti-neoplastic drugs such as cisplatin has resulted in considerable 
advances in the treatment of malignancies (Durant, 1980; Feigenbaum et al., 1989). 
It is used in patients with testicular, ovarian and bladder cancers, and also widely 
used in treating lung, head and neck, and oesophageal cancer (Kris et aL, 1989). 
However, nausea and vomiting are among the most distressing adverse effects of 
cancer chemotherapy (Tortorice & 0'Connell, 1990). In the 1980's, a survey of 56 
oncology centres reported that up to 10% of patients refuse chemotherapy because of 
the fear of chemotherapy-induced nausea and emesis (Maule & Perry, 1983). 
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1.3.3.1 Unfavourable effects associated with chemotherapy-induced nausea and 
emesis 
Chemotherapy-induced nausea and emesis has many unfavourable effects. The 
continual loss of gut contents by vomiting may produce malaise, malnutrition, 
oesophageal rupture, dehydration and electrolyte imbalance (Skeel & Lachant, 
1995). Complications like vertebral compression fractures and Mallory-Weiss tears 
of the esophageal-gastric mucosa may occur (Maule & Perry, 1983). It also reduces 
the bioavailability of orally administered cytotoxic and other drugs. Other frequently 
encountered problems such as loss of hair, tiredness, lack of energy, nausea and 
decreased sexual interest are additional reasons why patients may refuse continuation 
of treatment (Copper & Georgiou, 1992). � 
•»• 
In addition to the gastrointestinal disturbance, the specific use of cisplatin in man is 
associated with other toxic side-effects such as nephrotoxicity, hepatic toxicity, 
hematologic toxicity, otologic toxicity (Bryson, 1992), low white blood cell count 
and weight loss (Florczyk et al., 1982). These toxicological effects are also seen in 
other animals species including dog, monkey and rat (Schaeppi et al., 1973). . 
1.3.3.2 Anticipatory nausea and vomiting 
Anticipatory nausea and vomiting refers to emesis prior to initiation of treatment 
(Stewart, 1990). Anticipatory nausea and vomiting may be an important factor in a 
patient's decision to discontinue chemotherapy or to delay subsequent treatments 
(Morrow, 1984a). Anticipatory nausea and vomiting occurs in approximately 20-40 • 
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% of patients receiving cycles of chemotherapy (Dodds, 1985; Morrow, 1982). 
Patients may develop this type of emesis particularly if they have had severe nausea 
and vomiting during a previous chemotherapy course (Cubeddu, 1992). The sight or 
smell of the hospital ward, or materials associated with the administration of 
chemotherapy, may also provoke a conditioned response to result in the anticipatory 
nausea and/or vomiting (Singh et al., 1997). Such factors are difficult to replicate in 
an animal model. 
it 
1.3.3.3 Profile of cisplatin-induced emesis 
1.3.3.3.1 Acute Emesis 
Cisplatin is ranked as the most emetogenic chemotherapeutic agent (Table 1.3.2). In � 
a placebo-controlled trial, patients receiving cisplatin at a dose of 120 mg/m^ 
experienced nausea and vomiting, with a latency period of about 1- 3 h (Gralla et aL, 
1981). The most intense period of emesis lasted approximately 6-8 h from onset and 
the emetic intensity and frequency eventually declined with time. The initial phase 
occurring in the first 24 h period is usually referred to as the acute phase. 
1.3.3.3.2 Delayed emesis 
Nausea and vomiting occurring subsequent to acute emesis is classified as the 
delayed phase (Markham & Sorkin，1993; Stewart, 1990; Tortorice & 0’Connell’ 
1990). However, Clark and Gralla (Clark & Gralla, 1993) have suggested that 
delayed emesis may begin as early as 16 h after chemotherapy. This is supported by 
the evidence that 5-HT receptor antagonists are most active during the first 16-20 h 
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following cisplatin administration (Gralla, 1993). However, no firm evidence exists 
about how far the delayed period extends and it is generally thought to occur for a 
few to several days after therapy (Cunningham, 1997). Some reports indicate that 
the maximal intensity of emesis occurs on day 2 and day 3 (Chevalier-Evain et al., 
1994). Studies by Kris and co-workers reported that 20% patients still suffered from 
vomiting after 5 days (Kris et al., 1985). 
Delayed emesis is normally less severe than acute emesis but persists for a longer 
i> 
period. It has been shown to occur Jess frequently when good control of acute 
emesis has been achieved (Clark & Gralla, 1993; du Bois et al., 1992; Kris et al., 
1985; Kris et al., 1994; Tavorath & Hesketh, 1996). The physiology and 
mechanism(s) of delayed emesis remains unclear and may be different from that of � 
acute emesis (Gralla, 1993; Kris et aL, 1992). The delayed phase is often not as well 
controlled with the anti-emetic drugs that have proven to be "effective in acute 
emesis, and this significantly contributes to the distress associated with emetogenic 
chemotherapy (Tavorath & Hesketh, 1996). It has been suggested that delayed 
emesis may result from an accumulation of metabolites from the chemotherapeutic 
agents, tissue destruction, hypomagnesemia or gastritis (Clark & Gralla, 1993). 
L3J Animal Models of Cisplatin-Induced Acute and Delayed Emesis 
A number of studies on the acute emetic response induced by cisplatin have been 
carried out in animal models such as ferrets {Mustela putorius furo) (Costall et al., 
1987; Florczyk et a!., 1982; Rudd et al., 1996a; Tattersall et al., 1996), dogs (Foss et 
al., 1998; Fukui et al., 1992; Gylys et al., 1979; Ito et al., 1987)，cats (Lucot, 1989; 
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McCarthy & Borison, 1981; Miller & Nonaka, 1992; Smith et al., 1988)，monkeys 
(Fukui et al, 1993b; Working et al., 1998)，piglets (Grelot et aL, 1996; Milano et al., 
1995), pigeons (Feigenbaum et al., 1989; Navarra et al., 1992; Preziosi et al., 1992a; 
W o l f f & Leander，1994) and Suncus murinus (house musk shrew) (Matsuki et al., 
1993; Matsuki et al., 1988; Okada et al., 1995; Torii et al., 1991b). However, among 
the animal models mentioned, only piglets and ferrets are available for the study of 
cisplatin-induced delayed emesis. 
ii 
The pattern of the acute and delayed em^sis in the ferrets and piglets is similar to that 
observed in humans (Fukui & Yamamoto, 1999). In 1995, the piglet was proposed 
to be a suitable model to elucidate the delayed phase of cisplatin-induced (5.5 mg/kg, 
i.v.) emesis (Milano et al., 1995). However, the piglet model is not considered to be � 
as good as the ferret model since the entire phase of delayed emesis can be 
completely prevented by the repeated administration of the 5-HT3 receptor 
antagonist, granisetron (Grelot et al., 1996). However, as mentioned before, the 5-
HT3 receptor antagonists cannot provide satisfactory control of emesis in human. 
The ferret was first demonstrated to be suitable for the study of delayed-emesis in 
1994 (Rudd & Naylor, 1994). Other studies have suggested that methotrexate-
induced delayed emesis in the dog may also be useful to anti-emetic drug discovery 
(Fukui & Yamamoto，1999). In cats, the combination of granisetron and 
dexamethasone regimen is highly effective in antagonising cisplatin-induced emesis 
on days 1 and 2. In this model, granisetron is effective in antagonising emesis 
induced in 0-3 h but not the subsequent 4-24 h, and this is inconsistent with the cases 
in the clinic (Rudd et al, 2000). Therefore, the ferret is still considered to be the 
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most suitable predicator currently available for the clinical situation of cisplatin-
induced vomiting. 
1.3.5 Mechanisms and Pathways Involves in Chemotherapy-Induced Emesis 
The mechanism of cisplatin-induced emesis is not completely understood but is 
thought to involve both central and peripheral pathways. In the ferret, vagotomy 
inhibits 85% of the first 4 h of high-dose (10 mg/kg) cisplatin-induced emesis, 
fT 
indicating that abdominal vagal afferent nerves are the major pathways (Fukunaka et 
al., 1998). In most species, cisplatin has a latency of 1-2 h to induce emesis (Borison 
& McCarthy，1983). During this time, 5-HT is thought to be released from the 
、 
enterochromaffin cells (Torii et al., 1994). The locally released 5-HT has been 
hypothesised to stimulate 5-HT3 receptors on the vagal afferents (Read & Gwee, 
1994) and possibly 5-HT3 receptors in the central nervous system (Higgins et al., 
1989), thus leading to an increase in afferent input to the area postrema and nucleus 
tractus solitarius to finally cause emesis through an interaction with the vomiting 
centre. 
There is evidence in Suncus murinus that cisplatin may be metabolised to cis-
diaqodiammineplatinum (II) to induce emesis (Mutoh et al., 1992). The normal 
latency for cisplatin in these studies was 51.2 min but the metabolite rapidly induced 
emesis within 17.8 min. The metabolite was hypothesised to activate the emetic 
reflex via the production of free radicals that subsequently damaged the gut (Mutoh 
et al., 1992) or stimulated neural fibers (Cubeddu, 1992). These observations may be 
consistent with the action of cisplatin to induce the release of 5-HT in the ferret 
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(Stables et al., 1987) and guinea pig (Schworer et cd., 1991). Animal studies 
indicated that a number of anti-neoplastic agents can induce emesis via the 5-HT 
receptor pathway and they include cisplatin, antinomycin D, cyclophosphamide, 
dacarbazine, doxorubicin and mechlorethamine (Cunningham, 1997). 
In human, nearly 80% of the 5-HT body content is in the gastrointestinal tract, 95 % 
of which is in enterochromaffin (EC) cells. 5-HT is also distributed in platelets 
(11%) and the Raphe nucleus in the central nervous system (Cubeddu, 1992). It was 
suggested that the cisplatin-induced increase in 5-hydroxyindolacetic acid (5-HIAA), 
the main metabolite of 5-HT, originated from the enterochromaffin cells of the 
gastrointestinal tract since there was no significant change in the pool of platelet 5-
HT (Cubeddu, 1992). � 
In the Cubeddu study (1992)，after high-dose cisplatin infusion, increases in 5-HIAA 
levels were detected in the plasma and urine at 3-5 h following the start of 
chemotherapy. This phenomenon was in parallel with the onset and development of 
emesis. A marked increase in platelet-free plasma 5-HT levels was also 
demonstrated in 4 out of 10 patients receiving cisplatin (Barnes et cd., 1990). In the 
ferret, the administration of cisplatin caused a 100 % increase in the levels of 5-HT 
and 5-HIAA in the ileal mucosal (Gunning et cd., 1987)，but noradrenaline levels 
were unaffected. However, most of the studies were carried out using a relatively 
high-dose of cisplatin and in short observation period. 
5-HT3 receptor agonists are reported to induce emesis in Suncus murinus (Ito et al, 
1995; Torii et al., 1991a). However, the emetic response to 5-HT3 receptor agonists 
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in this species and others is prevented by bilateral vagotomy alone or in combination 
with splanchnicectomy in the ferret (Ravenscroft et al., 1992). This suggests that the 
5-HT3 receptor antagonists act at a peripheral site to inhibit cisplatin-induced emesis 
(Read & Gwee，1994). However, the central anti-emetic action of 5-HT3 antagonists 
cannot be discounted since 5-HT3 receptors are concentrated in the area postrema 
and nucleus tractus solitarius, and local injection of 5-HT3 receptor antagonists into 
these regions antagonises cisplatin-induced emesis (Higgins et al, 1989). 
. “ 
5-HT3 receptors have been identified in high density in the area postrema, nucleus 
tractus solitarius and subnucleus gelatinosus and in lower density in the dorsal motor 
nucleus of the vagus nerve and spinal trigeminal tract in a variety of species 
including humans fMaylor & Rudd, 1994; Naylor & Rudd, 1996). Some receptors � 
are located prejunctionally on vagal afferents in the nucleus tractus solitarius 
(Mitchelson, 1992a). Cisplatin may release 5-HT to act on these sites to induce 
emesis. 
However, a combination of bilateral vagotomy and greater splanchnic nerve section 
totally abolished cisplatin-induced emesis in the ferret (Andrews et al.，1990; Fukui 
et al., 1993a) and dogs (Fukui et cd., 1992). Lesions in dogs also inhibited 
completely the vomiting induced by cyclophosphamide, nitrogen mustard-N-oxide 
and actinomycin D (Fukui et al, 1993a). Vagotomy without splanchnicectomy 
completely inhibited cisplatin-induced emesis in Suncus murinus (Mutoh et al., 
1992), suggesting similarly between the pathways mediating cisplatin and 5-HT3 
receptor agonist induced emesis. 
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Lesion of the area postrema in the cat (McCarthy & Borison, 1984) and dog 
(Bhandari et al, 1989) prevents emesis induced by cisplatin (McCarthy & Borison, 
1980). Cisplatin administration into the cerebroventricular system of cats can induce 
emesis (Smith et al., 1988). This provides evidence that the area postrema is 
involved in the emetic mechanism of action of cisplatin. Alternatively, pathways 




1.3.6 Anti-Emetic Drugs for the Treatment of Chemotherapy-Induced Emesis 
It has been suggested that no single agent can provide complete protection from the 
、 
various emetic phases of chemotherapy (Ettinger，1995). Anti-emetic regimens and 
the management of nausea and vomiting depend on different situations. 
In the past, phenothiazines and butyrophenones had a definite role in moderately 
inhibiting chemotherapy-induced emesis. Other anti-emetic agents, such as 
corticosteroids, benzodiazepines，high-dose of metoclopramide and cannabinoids 
were increasingly used (Allan, 1987). More recently, the 5-HT3 receptor antagonists 
have superseded the older drugs as they are more effective and have fewer side-
effects. However, they are commonly combined with other anti-emetics. 
1.3.6.1 5-HTs receptor antagonists 
In the 1980s，prior to the use of 5-HT3 receptor antagonists, a common anti-emetic 
therapy was the combination of metoclopramide and dexamethasone in the clinic 
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(Ettinger, 1995; Gralla, 1993). Metoclopramide is a substituted benzamide and was 
originally thought to control emesis via blockade of dopamine receptors. Later 
research revealed that the mechanisms of action may have more to do with 
antagonism of5-HT3 receptors than antagonism of dopamine D2 receptors (Costall et 
al., 1987). However, metoclopramide losses efficacy against highly emetogenic 
drugs (Ettinger, 1995) and must be used at high doses in order to block the 5-HT3 
receptor. 
1« 
Clinically, a number of 5-HT3 receptor antagonists are now available in oral and 
intravenous formulations. However, they are generally more expensive than other 
anti-emetic drugs. They have been reported to inhibit cisplatin-induced emesis in 
animal models including ferrets (Higgins et al., 1989; Rudd & Naylor, 1996), cats � 
(Rudd et al., 2000), dogs (Fukui & Yamamoto, 1999) and Suncus murinus (Gardner 
& Perren, 1998). Currently, the combination of a selective 5-HT3 receptor antagonist 
and a corticosteroid represents the anti-emetic treatment of choice with 
chemotherapy regimens that have moderate to high emetogenic potential (Gandara et 
al., 1998). 
5-HT3 antagonists are efficacious and have a good safety profile to control acute 
emesis. However, they are not very effective to control delayed emesis (Kris et al., 
1992; Lecomte et aL, 1994). There is also a decrease in efficacy with these 
compounds during multiple-day or after several cycles of chemotherapy (Aapro, 
1993; Chevalier-Evain et al., 1994). Ondansetron was the first of this class of anti-
emetic drugs to become available in 1991 and granisetron for intravenous 
administration became available in 1994 (Ettinger, 1995). Markham & Sorkin 
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(Markham & Sorkin, 1993) reviewed several studies showing ondansetron to be a 
more effective anti-emetic agent than high-dose metoclopramide in patients with 
emesis induced by high and low doses of cisplatin treatment and non-cisplatin 
chemotherapy-induced emesis. Although ondansetron and granisetron are superior to 
metoclopramide in inhibiting cisplatin-induced emesis (Balfour & Goa, 1997; 
Bonneterre et al., 1990)，metoclopramide remains an option in combination with 
other effective agents or when other drugs fail (Bonneterre et al.’ 1990). 
It 
In summary, 5-HT3 receptor antagonists produce a major improvement in 70 to 80% 
of patients to control the acute phase of cisplatin induced-emesis (Lecomte et al., 
1994). Studies with 5-HT3 receptor antagonist plus corticosteroids show advantage 
over 5-HT3 antagonist alone (see Table 1.3.3). � 
1.3.6.2 Dopamine receptor antagonists 
For many years, dopamine receptor blockers such as phenothiazines, butyrophenones 
and substituted benzamides have been among the most effective anti-emetic agents 
(Goodman, 1997; Gralla, 1989). 
7.5.6.2.1 Phenothiazines 
Phenothiazines such as prochlorperazine have been used in combination anti-emetic 
regimens for many years and remain to be important options for patients who 
experience acute and delayed nausea (Maule & Perry, 1983; Wampler, 1983). They 
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exhibit modest activity in the treatment of emesis produced by a number of mild 
emetogenic cytotoxic agents, but have limited value in the treatment of patients on 
moderately to highly emetogenic agents (Bakowski, 1984). 
The use of phenothiazines alone for chemotherapy-induced emesis is limited. 
However, combination with other anti-emetic agents can improve emetic protection. 
For example, they provided an increase in efficacy when combining tropisetron 
(Bregni et al, 1991; Lebeau et al., 1997) and steroids (Aapro, 1991; Herrstedt & 
Dombernowsky, 1994), and provide a reduction of both the acute and delayed phase 
of chemotherapy-induced emesis. 
% 
1.3.6.2.2 Butyrophenones 
The butyrophenones, such as haloperidol and droperidol are also commonly used 
(Fujii et al., 1998). These drugs are major tranquilizers. Their anti-emetic action is 
not completely understood but probably involves dopaminergic blockade (Goodman, 
1997). They are particularly helpful when anxiety and anticipatory symptoms 
aggravate the degree and intensity of nausea and vomiting (Goodman, 1997). There 
are studies suggesting that the efficacy of droperidol/granisetron combination is 
superior to that of droperidol or granisetron alone in prevention of postoperative 
nausea and vomiting (Mitchelson, 1992a). 
They appear to be as effective in preventing nausea and vomiting as phenothiazines 
(Goodman, 1997). However, in some cases, haloperidol was reported to be more 
effective than prochlorperazine fNeidhart et al., 1981). 
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1.3.6.2 •？ Domperidone 
Domperidone, derived from the butyrophenones, has demonstrated activity against 
moderately emetogenic stimuli (Bakowski, 1984). Being a D2 receptor antagonist, it 
blocks apomorphine-induced emesis and the site of action is believed to be located 
within the area postrema and the chemoreceptor trigger zone (Andrews et al., 1988; 
Barone，1999). As very little domperidone crosses the blood-brain barrier, reports of 




The benzodiazepines are involved in controlling anticipatory nausea and 
chemotherapy-induced anxiety, but they have little anti-emetic activity (Andrews et 
al., 1988). Lorazepam and diazepam produce favourable results for anticipatory 
emesis by inducing amnesia and blocking the causative stimuli (Tortorice & 
0'Connell, 1990). The sedative and anxiolytic actions of benzodiazepines are thus 
suggested to contribute their useful anti-emetic effect (Laszlo et al., 1983). It has 
also been suggested that the anti-emetic activity is related to the reduction of the 
function of 5-HT in the central nervous system (Costall et al., 1987). 
1.3.6.4 Cannabinoids 
Interest in the cannabinoids as anti-emetics was first aroused by anecdotal reports of 
patients with cancer claiming relief from chemotherapy-induced emesis after 
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smoking marijuana. These observations led to several controlled trials, starting in 
1975 (Sallan et al., 1975). At present, both inhaled and ingested drugs have shown 
benefits (Maule & Perry, 1983; Tortorice & 0,Connell, 1990)，although they have 
poor bioavailability due to the first-pass effect (Mattes et al., 1993). The 
cannabinoids suppress mild to moderate chemotherapy-induced emesis. Two 
cannabinoids, dronabinol and nabilone, and other synthetic compounds are available 
(Tortorice & 0'Connell, 1990). They have been considered more efficacious than 
prochlorperazine in the treatment of emesis induced by more severe emetogenic 
stimuli (Bakowski, 1984). 
The mechanism of action is unknown, but, is likely to involve cannabinoid receptors 
although some authors have suggested a role for the ^-opiate receptor (Costello & � 
Borison, 1977; Harris, 1982; Tortorice & O'Connell, 1990). Their sedative and 
dysphoric effects may also contribute to the control of emesis (Andrews et al., 1988). 
1.3.6.5 Antihistamines and anticholinergics 
The anti-emetic action of antihistamines and anticholinergics probably involves 
histamine Hi and muscarinic- receptors located in the emetic and vestibular centres 
of the brain (Dodds, 1985). They have limited efficacy against chemotherapy-
induced emesis. However, they are useful in reducing extrapyramidal side-effects of 
dopamine antagonists (Bakowski, 1984). The addition of transdermal scopolamine 
to a standard regimen of metoclopramide and dexamethasone was demonstrated to 
provide additive benefit in the control of cisplatin-induced emesis (Meyer et al., 
1987). 
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1. S. 6.6 NKi receptor antagonists 
Although 5-HT is important in mediating cytotoxic-induced emesis, there is evidence 
suggesting that other mediators, including substance P, have a role in the emetic 
reflex. A high concentration of substance P is found in the brain stem regions 
associated with vomiting, including the area postrema and the nucleus tractus 
solitarius (Armstrong et al., 1981; Rupniak & Kramer, 1999). Recently developed 
tachykinin neurokinini O^Ki) receptor antagonists can antagonise chemotherapy-
induced emesis. , 
A central site of action o f N K i receptor antagonists has been suggested by Tattersall 
et al. who showed that local injections of the NKi receptor antagonists, L-741,671 � 
and L-743,310 into nucleus tractus solitarius could inhibit cisplatin-induced emesis 
•» 
(Tattersall et al., 1996). GR82334 also antagonised cisplatin-induced emesis after 
injection into the ferret hind brain, in the region of the nucleus tractus solitarius 
(Gardner etal., 1994). 
Further research has demonstrated that selective NKi receptor antagonists, such.as 
CP-99,994, GR203040, GR 205171，CP122,721 and sendide, are effective in the 
inhibition of cisplatin- (Bountra et al., 1993; Gonsalves et al., 1996; Minami et aL, 
1998; Tattersall et al., 1993) and cyclophosphamide-induced acute emesis in the 
ferret and Suncus murinus (Gardner et al., 1996; Gardner et al., 1995). CP-99,994 
and PD 154075 were able to markedly attenuate both acute and delayed emesis 
induced by cisplatin in the ferret (Rudd et al., 1996b; Singh et a!_, 1997; Tattersall et 
a/.，2000). Clinical trials with CP122,721 (Kris et al., 1997), L-754,030 fNavari et 
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fl/., 1999) and CJ-11,974 (Hesketh et al., 1999) have recently confirmed their 
effectiveness in preventing delayed emesis after cisplatin chemotherapy. 
1.3.6.7 Corticosteroids 
Adrenal corticosteroids were first reported in 1979 to have anti-emetic effect in 
cancer chemotherapy (Cersosimo & Karp, 1986). Corticosteroids alone are effective 
. i> 
anti-emetics for moderately emetogenic chemotherapy in both acute and delayed 
产 
phases (Goodman, 1997). Both dexamethasone and methylprednisolone alone or in 
combination with other anti-emetics are widely used in the clinic (Fauser et al., 
1999). They are relatively inexpensive and provide an additive or synergistic effect 
、 
when combined with 5-HT3 receptor antagonists and dopamine receptor antagonists 
against moderately or highly emetogenic chemotherapy (Fauser el al, 1999). They 
are especially useful during the delayed phase, which is not particularly sensitive to 
5-HT3 receptor antagonists. There are many reports demonstrating the additive 
effect of corticosteroids with 5-HTs receptor antagonists and some are listed in Table 
1.3.2. 
The anti-emetic mechanism of corticosteroids is unknown. It has been suggested that 
the mechanism may involve a reduction of arachidonic acid biosynthesis (Andrews et 
al., 1988) or prostaglandin synthesis (Rich et cd., 1980). Investigations have shown 
that indomethacin can relieve radiation-induced emesis in the dog (Carpenter et al, 
1986) and the non-steroid anti-inflammatory drug (NSAID), ibuprofen, has been 
used in controlling radiotherapy-induced emesis in the clinic (Stryker et al., 1979). 
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Another possible mechanism of the anti-emetic action ofcorticosteroids is to activate 
hepatic tryptophan pyrrolase and shunt the metabolism of tryptophan away from the 
5-HT synthetic pathways, thus decreasing 5-HT turnover in the central nervous 
system (Young, 1981). It has been suggested that dexamethasone can also reduce the 
permeability of the blood-brain barrier and hence reduce the penetration of emetic 
agents to the brain or reduce cerebral oedema that may be caused by cytotoxic drugs 
and radiation (Andrews et al, 1988; Liu et al., 1998). 
ii 
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1.3.6.8 Multi-agent anti-emetic regimens 
There have been attempts to use ‘cocktail，anti-emetic therapy. Successful 
、 
termination ofcisplatin-based chemotherapy has been reported using 5 potential anti-
emetic agents (Plezia et al., 1984). However, selective 5-HT3 receptor antagonists 
and corticosteroids are the two drug classes that are most effective and are 
convenient to use. Their combination is now considered the standard for the care and 
prevention of emesis arising from moderately to highly emetogenic chemotherapy 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.4 Motion-Induced Emesis 
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1.4,1 Incidence 
Motion sickness can be experienced by individuals travelling in boats, automobiles 
or aircraft and can even occur in stationary individuals exposed to a moving visual 
scene (Yates et al., 1998). In addition, motion sickness is also frequently reported by 
astronauts in zero gravity conditions (Miller, 1991). The signs and symptoms 
experienced during motion sickness include nausea and vomiting and this may be 
t* 
associated with pallor, cold sweating and sometimes headaches and drowsiness 
fT 
(Money, 1970). Other subtle changes include alterations in heart rate, blood 
pressure, respiration rate, gastric motility, body temperature and glucose status 
(Balaban，1996; Galle, 1981; Holtmann et al., 1987; Lerman et al., 1992; Oman, 
1990; Tyler & Bard, 1949). Motion sickness can evoke changes in an individual's 
behaviour and this may impact on their performance and quality of life. 
Not all individuals will experience ‘sickness，when exposed to motion. Moreover, 
some individuals will experience mild symptoms of motion sickness compared to 
others that experience severe symptoms culminating in vomiting episodes (Tyler & 
Bard, 1949). A survey of 20,029 "nationality" passengers at sea revealed that 21 % 
felt unwell with 7 % experienced vomiting (Lawther & Griffin, 1988). A more recent 
survey questioned 3256 coach "nationality" travellers and revealed that 28.4 % of 
them experienced illness during the journey with 1.7 % experienced vomiting 
(Turner & Griffm，1999). However, an individual may also experience different 
degrees of motion sickness depending on the characteristics of the motion stimulus 
(e.g. intensity and frequency of the stimulus) (Javid & Naylor，1999; Lawther & 
Griffm, 1987). An individual's susceptibility may also be influenced by age (Cheung 
42 
& Money，1992), gender (Matsuki et al, 1997)，race (Tyler & Bard, 1949), aerobic 
fitness (Jennings et al., 1988)，vestibular asymmetry (Lackner & Graybiel，1984; 
Lackner et al, 1987)，hormone (Koch, 1999) and neurotransmitter levels (Takeda et 
a/., 1989). Prior experience with the motion stimulus may lead to adaptation or 
desensitisation (Hu & Hui，1997; Javid & Naylor, 1999; Tyler & Bard, 1949). People 
who suffer from migraine are also more likely to experience motion sickness 
(Golding, 1998; Li et al., 1999). Finally, there is also evidence suggesting that 
hereditary factors could contribute to an individual's susceptibility to motion 
sickness (Koch, 1999). . 
Patients who are known to experience motion sickness also seem more likely to 
develop emesis to other challenges. For example, there is a significant correlation 
between patients' susceptibility to motion sickness and the development of 
»* 
anticipatory nausea and vomiting in patients receiving chemotherapy (Golding, 1998; 
Morrow, 1984b). There also seems to be a similar correlation between motion 
sickness susceptibility and the incidence of post-operative nausea and vomiting (Fujii 
e/ al., 1999). This suggests that the emetic circuitry in people who experience motion 
sickness is rather sensitive to emetogenic challenge. . 
1' 4.2 Mechanisms and Path ways In volved in Motion Sickness 
Motion sickness is generally thought to occur as a result of a sensory conflict or 
rearrangement between information arising from the semicircular canals and otolith 
organs of the vestibular system, visual, and other sensory input, and the input that is 
expected on the basis of past experience or exposure history (Miller, 1991). Implicit 
43 
in the conflict theory is the hypothesis that neural and/or humoral signals originate in 
regions of the brain subserving spatial orientation, and that these signals somehow 
traverse to other centres mediating sickness symptoms (Oman, 1990). However, this 
theory does not explain motion sickness induced by all conditions (Yates et al., 
1998). 
Apart from the necessity of the vestibular apparatus and certain motor outputs, the 
essential roles ofvarious central nervous system structures and transmitter systems in 
producing motion sickness are unknown (Miller, 1991). Yates et al., (1998) 
summarised a number of neurotransmitters and neuromodulators that influence the 
activity of vestibular nucleus neurons. They include acetylcholine, glutamate, 
glycine，gamma-aminobutyric acid (GABA), histamine, noradrenaline, dopamine, 5-
HT, substance P, somatostatin, ACTH and enkephalin. 
1.4.2.1 Importance of the vestibular apparatus 
The vestibular apparatus is essential for the production of motion sickness (Money, 
1970; Taillemite et al., 1997; Tyler & Bard, 1949). Wood et al. summarised the 
mechanism of action as the following: impulses are transmitted from the vestibular 
receptors to the vestibular nuclei, the older areas o f t h e cerebellum, and to the brain 
stem reticular areas. The vestibular stimulation eventually results in the activation of 
the vomiting centre (Wood et al., 1981). 
Vestibular stimulation using a sinusoidal electrical polarisation technique of the 
labyrinths of decerebrated cats, produced vomiting and related activity resembling 
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that seen in motion sickness (Miller & Wilson, 1983). In the same study, however, it 
was found that nodulus and uvula were not essential for vestibular-induced vomiting. 
This is in contrast to older studies conducted by Wang and Chinn in 1956. In dog, 
the removal of vestibular apparatus of the inner ear resulted in the reduction of the 
emetic response to certain poisons (Money & Cheung, 1983). Labyrinthectomized 
squirrel monkeys failed to vomit following rotation and zero gravity of parabolic 
flight (Thach & Graybiel, 1968; Wilpizeski et al., 1987). 
1« 
In man, motion sickness is thought,to arise from stimulation of labyrinthine 
structures in the inner ear. For example, it has been known for over a century that 
individuals who lack inner ear vestibular function are immune to motion, as first 
demonstrated by James in 1882 (cited by Chinn & Smith, 1955). Deaf-mutes, and 
persons with internal ear damage were reported immune to motion sickness (Tyler & 
Bard, 1949). Humans with labyrinthine dysfunction were reported not to experience 
space sickness (Lathers et al., 1989). 
1.4.2.2 Importance of the area postrema 
The role of the area postrema in motion sickness is not completely resolved 
(Crampton, 1993). For example, 8 out of 12 dogs were protected from vomiting 
induced by swinging after destruction of the chemoreceptor trigger zone (cited by 
Money, 1970). Ablation of the area postrema in squirrel monkey significantly 
reduced the incidence and frequency of motion-induced emesis, with 5 out of 8 
ablated animals showing no emetic response (Brizzee et al., 1980). However, lesions 
(Borison，1985) and ablation (Borison & Borison, 1986) o f the area postrema are not 
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effective in preventing motion sickness in cats. Further, motion-induced vomiting 
and conditioned taste aversion still occur after ablation of the area postrema in cat 
and monkey (Fox et al., 1990; Wilpizeski et al., 1986). Recently, it was suggested 
that the area postrema is not essential for vomiting induced by motion (Miller & 
Leslie, 1994; Takeda et al., 1995) and that motion-induced vomiting was prevented 
in other studies because the area postrema lesions also extended into the underlying 
nucleus tractus solitarius (Yates et al., 1998). 
II 
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1.4.2.3 The nucleus tractus solitarius 
There is evidence that the nucleus tractus solitarius receives afferent inputs from the 
vestibular apparatus. In the cat, neurons with vestibular inputs receive convergent 
signals from the abdominal vagus nerve and may potentially mediate motion 
sickness-related vomiting (cited by Yates et al., 1994). However, the vagus nerve is 
not essential for motion-induced emesis (Wang et al., 1957) but the nucleus tractus 
solitarius may represent a key brain area in the mediation ofmany causes ofemesis. 
1.4.2.4 Hormone and neurotransmitters 
Endogenous cortisol, ACTH, adrenaline, noradrenaline, growth hormone, prolactin 
and vasopressin have been shown to be elevated after exposure to motion 
(Eversmann et a!., 1978; Grigoriev et al., 1988; Janowsky et al, 1984; Koch, 1999. 
Kohl, 1985b; Kohl, 1987; Takeda et al., 1990). There are also reports ofincreases in 
the urinary output of thyroid hormones, with the accompanying decreases in serum 
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levels of thyroid stimulating hormone (TSH) (Habermann et al.’ 1978) after motion. 
Conversely, lower baseline levels of dopamine, uric acid, 5-HT and vasopressin are 
associated with an increased incidence ofvomiting in the cat (Lucot et al, 1989). 
1*4.3 Animal models in Motion-Induced Emesis 
Both emetic and non-emetic species have been used to elucidate the mechanism(s) of 
\* 
motion sickness. The non-emetic species include the rat (Hasegawa et al., 1992) and 
guinea pig (Ikeda & Takahashi，1997; Ossenkopp & Ossenkopp, 1990; Parker, 
1977). The illness-response behaviour such as kaolin intake (pica) and motion-
induced conditioned taste aversion models have been used as the index of motion 
sickness. Furthermore, the pigeon, which is immune to motion sickness has been 
exposed to microgravity to measure a disorientation response (Mori, 1995; Tyler & 
Bard, 1949). In addition, the rabbit has been exposed to seasickness to elucidate the 
mechanism of motion sickness (Maksimuk & Skoromnyi, 1990; Skoromnyi, 1987. 
Skoromnyi, 1989; Skoromnyi etal., 1986; Wada, 1991). 
Species that have a vomiting reflex include the squirrel monkey (a non-human 
primate) (Brizzee & karashi, 1986; Cheung et al., 1994; Cheung et al, 1992， 
Wilpizeski，1986 #1756), dog (Cheung et aL, 1994) and cat (Fox et al., 1987; Lucot, 
1998a; Lucot et al., 1997; Pei et al., 1992). In 1988, a smaller animal, Suncus 
^urinus was introduced as a new model to use for motion-induced emesis research 
(Ueno et al., 1988) and is now a very popular model (Javid & Naylor, 1999. 
Kakimoto et al., 1997; Okada et al., 1996; Rudd et al, 1999b). The amphibian, frog 
and salamanders (Wassersug et al., 1993) have also been reported to exhibit motion-
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induced vomiting but they are seldom used in research. Horses, cows, sheep, 
chicken，(cited by Tyler & Bard, 1949)，ferrets, seals, birds (cited by Javid & Naylor， 
1999)，fish and chimpanzees (Miller, 1991; Money, 1970) have been reported to 
suffer from motion sickness. 
Suncus murinus is a small animal (<90g) that is very sensitive to provocative motion. 
They are a member of the Insectivora and are considered to be closer to primates 
than rodents and carnivores in the phylogenetic system (Ueno et.al., 1987). Their 
small size provides an advantage over other large species used in motion-induced 
vomiting research. For example, they require smaller-scale apparatus for generating 
motion stimulus than for the large animals. 
1'4.4 Anti-Emetic Drugs for the Treatment of Motion Sickness^ 
Antihistamines, antimuscarinics and sympthomimetics drugs are currently used to 
control motion-induced vomiting in humans (Taillemite et al., 1997; Yates et al, 
199¾. Drugs are taken prior to the exposure of motion but their precise sites of 
actions are still unclear (Lucot, 1998b; Yates et al., 1998). The most common 
assertion is that they suppress integration of sensory stimuli in the vestibular nuclei 
(Lucot, 1998b). Diphenhydramine and dimenhydrinate were demonstrated to 
suppress the generation of electrical potentials in the vestibular nuclei elicited by 
stimulation of the vestibular apparatus (Jaju & Wang, 1971). An action on afferent 
pathways from cortical and limbic regions has also been suggested (Mitchelson, 
1992b) but an action at the chemoreceptor trigger zone and vestibular apparatus is 
more likely. 
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1.4.4.1 A ntichol inergics 
Cholinergic pathways have been associated with both the perception and expression 
of normal and excessive levels of motion stimuli (Kohl & Homick, 1983). Atropine 
is useful in man but the most common antimuscarinic drug in clinical use is 
scopolamine (hyoscine). It is a competitive antagonist of cholinergic muscarinic 
receptors and is considered as the best single anti-motion sickness drug in preventing 
air, sea and space sickness (Cheung et al., 1992; Chinn & Smi th�1955; Clissold & 
Heel, 1985; Lucot, 1998b; Mitchelson, 1992b; Shashko et al., 1999; Tokola et al., 
1984). Scopolamine is effective in animal models such as monkey (Cheung et al., 
1992), Suncus murinus (Ueno et al., 1988) and rat (Morita et al., 1988). Transdermal 
scopolamine has been developed to minimise the incidence of side-effects such as 
drowsiness and to enhance the absorption process. The rate of drug entry into the 
systemic circulation was reported over an extended period (72 hours) (Clissold & 
Heel, 1985; Honkavaara, 1996). It blocks all five subtypes of muscarinic receptors, 
but the efficacy is suggested to be mediated by blocking M3 and M5 receptors. This 
view is supported by the anti-emetic action provided by zamafenacin, a M3 and M5 
receptor antagonist, in man (Stott & Golding，1994) and the failure of idaverine, a 
M1/M2 selective antagonist to prevent motion-induced emesis in cats (Lucot et al., 
1991). 
1.4.4.2 Antihistamines 
Antihistamines represent another class of anti-emetic drug that are commonly used in 
man (Serafin et al., 1993; Taillemite et al., 1997; Yates et al., 1998). They have a 
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better and higher safety profile than the anticholinergics and a longer duration of 
action, but are less efficacious (Lucot, 1998b). 
They are probably effective because they block Hi receptors in vestibular nuclei and 
there is evidence that provocative motion induces increases in histamine levels in 
vestibular (Kaji et al., 1991). Histamine transmission has been demonstrated to play 
a role in motion sickness in animal models. For example, depletion of histamine 
with the irreversible histamine synthesis inhibitor, alpha-fluoromethylhistidine (a-
FMH), reduced motion sickness in Suncus murinus (Kaji et al., 1991) and the cat 
(Lucot & Takeda, 1992) and suppressed kaolin intake in rats (Takeda et al., 1986). 
The histaminergic system is particularly active in the telencephalon and 
diencephalon in Suncus murinus (Kaji et al., 1991). However, the affinity of the anti-
histamines for histamine receptors does not seem to correlate well with their ability 
to suppress motion sickness (Lucot, 1998b). 
Experimental findings suggest that vestibular signals activate histaminergic neurons 
via a cholinergic pathway and this neuronal circuit is involved in the vestibulo-
autonomic response (Horii et al., 1995). However, a block of histamine receptors in 
the central nervous system is also associated with sedation and this action may also 
contribute to the anti-emetic mechanism of action. Meclozine (meclizine) is one of 
the principal agents used to control space sickness (Clissold & Heel, 1985; Jennings, 
1998). 
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/. 4.4,3 Non-selective muscarinic and histamine receptor antagonists 
Drugs that have both antimuscarinic and antihistamine properties are commonly used 
to prevent motion sickness. They include promethazine (Davis et al., 1993; 
Jennings, 1998)，dimenhydrinate (Parrott, 1989) and diphenhydramine (Inokuchi et 
fl/.，1999). Promethazine, a phenothiazine, which may produce some drowsiness and 




Ephedrine was reported to be effective to reduce symptoms of motion sickness in 
man (Sunahara et al., 1987; Wood et al., 1990) and rabbit (Skoromnyi, 1987). It also 
relieves the drowsiness produced by antihistamines (Wood et al., 1981). Ephedrine 
in combination with other anti-emetic drugs such as scopolamine (Graybiel et al., 
1981; Laitinen et al., 1981) and promethazine (Graybiel et al., 1976; Graybiel et al., 
1975) have proved useful in the prevention of motion sickness in man. Ephedrine 
plus pipolphen (promethazine hydrochloride) was reported to be effective in altering 
the orthostatic tolerance in patients with vestibular/autonomous syndrome (Nishiike 
et al.，1995; Shashko et al., 1999). The anti-emetic action of amphetamine is also 
seen in Suncus murinus (Ueno et al., 1988). 
1.4.4.5 NKi receptor antagonists 
Only a few studies have examined the anti-emetic potential of NKi receptor 
antagonists to prevent motion-induced emesis. A number of structurally diverse NKi 
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receptor antagonists were found effective against motion-induced emesis in Suncus 
murinus (Gardner et al., 1995; Rudd et al., 1999b). Further, NK, receptor 
antagonism also inhibited motion-induced vomiting in the cat but did not change the 
autonomic signs, suggesting an action late in the emetic motor pathway (Lucot et al., 
1997). 
1.4.4.6 5-HTiA agonists 
it 
r 
5-HTiA agonists are also reported to produce a broad inhibition of emesis in the cat 
(Foreman et al., 1993; Lucot, 1990; Lucot, 1994). 5-HT!A agonists including 8-
hydroxy-2-(di-n-propylamino)tetrarin (8-OH-DPAT), 4_(4_[4_(2_ 
pyrimidinyl)piperazin-l-yl]butyl)-23,4,54etrahydro-l,4-benzoxazepine-3,5-dione 
(SUN8399), buspirone, gepirone, ipsapirone and tandospirone, ^dose-dependently 
reduced motion-induced emesis in Suncus murinus (Okada et al., 1994). It has been 
suggested that the mechanism involved an activation of inhibitory 5-HTiA receptors 
in the vestibular nuclei and the emetic motor pathway (Yates et al., 1998). 
1.4.4.7 5-HTireceptor agonist 
(+/-)-1 -(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT2A/5-HT2c 
receptor agonist, dose-dependently prevented motion sickness in Suncus murinus 
(Okada et al., 1995). However, the potentail for DOI use in the clinic is low because 
of its hallucinogenic side effects (Glennon et cd., 1982). The anti-emetic effect was 
suggested to be mediated by 5-HT2 receptors in the central nervous system, since a 
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peripherally acting 5-HT2A/2c receptor agonist, a-Me-5-HT, was not anti-emetic 
(Okada etal., 1995). 
1.4.4.8 Arginine vasopressin (A VP) antagonists 
Plasma vasopressin is known to increase in both susceptible- and motion-sickness-
resistant subjects exposed to motion (Eversmann et al., 1978; Kim et al., 1997; Koch 
et a l , 1990; Kohl, 1987). However, subjects displaying no nausea and/or no emesis 
ff 
demonstrated smaller elevations in plasma vasopressin levels (Fox et al., 1987; 
Koch, 1999; Kohl, 1987; Xu et aL, 1993). The contribution of vasopressin to 
motion-induced nausea is suggested to occur within the brain and may involve the 
release of acetylcholine and muscarinic receptors. Arginine vasopressin APVi 
antagonists significantly reduced motion sickness in monkey (Cheung et al.’ 1994; 
Cheung et al., 1992; Kohl & MacDonald, 1991). 
1.4.4.9 Opioid receptor agonists 
Endogenous opioids may be involved in the development of motion sickness (Drozd 
Iu et al., 1988). Studies indicate that ^i-, 5- and K- opioid receptors located in the area 
postrema and / or nucleus tractus solitarius are involved in the emetic reflex (Rudd et 
al., 1999a). It has been suggested that K and/or ^ receptors at the level of the 
vomiting centre may mediate an inhibition of emesis, whereas 6 opioid receptors in 
the area postrema could be involved in motion-induced emesis (Kohl & MacDonald, 
1991). 
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Morphine was shown to prevent motion sickness in Suncus murinus (Kakimoto et 
a/.，1997). Conversely, naloxone, a ^-opioid receptor antagonist, increases the 
frequency of motion sickness symptoms in cat (Crampton & Daunton, 1983) and 
man (Allen etal., 1986). 
1.4.4.10 Dexamethasone and hormone levels 
Physical or psychological stress situations involve most of the endocrine systems. 
� 
Provocative motion is known to elevate the plasma levels of cortisol and ACTH 
(Grigoriev et aL, 1988; Janowsky et aL, 1984). The changes have been considered to 
occur because of the stress induced by motion (Kohl, 1985b; Lathers et al., 1989). 
It is interesting that the synthesis of noradrenaline and adrenaline by the adrenal 
medulla is regulated by glucocorticoids from the adrenal cortex. (Kohl, 1985b; Kohl, 
1987; Takeda et aL, 1990). People with resistance to motion sickness have greater 
elevations of noradrenaline and adrenaline levels than individuals who are 
susceptible to motion sickness (Kohl, 1985b). 
Dexamethasone has been reported to be effective in antagonising motion-induced 
nausea and vomiting in man but the mechanism is unknown (Kohl, 1985a; Kohl, 
1986). The action may be related to hormonal changes that are under the influence 
of hypothalamic-pituitary-adrenal (HPA) axis since dexamethasone mimics the 
action ofcortisol and reduces the release of ACTH (Kohl & MacDonald, 1991). 
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1.4.4.11 Other anti-emetic drugs 
There are other kinds of drugs that are known to be effective to reduce motion 
sickness in animal models. These include ginger (Grontved et al, 1988; Qian & Liu, 
1992; Stewart et al., 1991), lorazepam (a benzodiazepine), sodium bromide and 
barbiturates (Babkin et al, 1946; Lucot & Crampton, 1989; Nobel, 1948). Also, N-
methyl-D-aspartate 0^MDA)-receptor antagonists were found to be effective in 
preventing motion sickness in cat (Lucot, 1998a). 
fi-
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1.5 Aims of the Studies 
There is evidence suggesting that corticosteroids are useful drugs to reduce nausea 
and vomiting induced by cancer chemotherapy. There is also evidence suggesting 
that corticosteroids modulate motion-induced emesis. However, for such a useful 
group of compounds, it is surprising that so little is known about the mechanism of 
anti-emetic action. Several hypotheses have been proposed but not have been based 
I* 
on thorough investigation and are therefore essentially speculative. Indeed, the anti-
产 
emetic potential of a corticosteroid to reduce delayed emesis, in an animal model, 
was not clearly identified until 1996 (Rudd & Naylor, 1996). 
There are several aims of the present studies. The primary aim was to determine the 
rank order ofinhibitory potency of several corticosteroids to reduce the acute (day 1) 
and delayed (days 2-3) retching and vomiting response induced by a single dose of 
cisplatin in the ferret. Such studies were considered central to differentiating 
between the role of glucocorticoid and mineralocorticoid receptors in the emetic 
response. This approach was also extended to include the potential for 
corticosteroids to reduce motion-induced emesis in Suncus murinus. 
The studies in both species were also aimed at identifying the optimal doses of the 
corticosteroids to inhibit emesis in the models and to identify any distinct 
corticosteroid sensitive phases in the emetic responses (particularly for cisplatin-
induced emesis). 
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Other studies also looked at the anti-emetic action of the corticosteroids in more 
detail. Corticosteroids are known to reduce the production of prostanoids and 
leukotrienes and the contribution of this to anti-emesis was unknown at the start of 
this project. Studies were therefore designed to selectively reduce prostanoid and 
leukotriene synthesis to attempt to mimic the action of corticosteroid treatment. 
Indomethacin was selected as a reference non-selective inhibitor of the 
cycloxygenase enzyme and the selective cycloxygenase-2 inhibitors, DFU and L-
745，337 were also used. The role of the leukotrienes was selectively assessed using 
the 5-lipoxygenase activating protein (FLAP)-inhibitor, MK-886. 
There have been studies in the clinic with synthetic ACTH analogues that suggest 
that modulating endogenous cortisol function is effective to reduce chemotherapy-
induced emesis (Battelli et cd., 1984). The rationale is that an ACTH-induced 
increase in endogenous cortisol mimics the administration of synthetic 
corticosteroids. The present studies aimed to replicate the findings in the ferret using 
the synthetic ACTH analogue, cortrosyn (ACTH 1-24). Studies were also designed 
to assess the importance of endogenous cortisol to the emetic response by using the 
cortisol synthesis inhibitor, metyrapone. 
The administration of corticosteroid to an animal can affect endogenous ACTH and 
cortisol levels. The role of the changes in the hormone levels to anti-emesis is also 
unknown. Some studies were therefore designed to investigate if the anti-emetic 
action of the corticosteroids could be dissected from the known modulatory role on 
ACTH and cortisol function. 
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In summary, the aims of the studies were to provide information relevant to the 
dissection of the mechanism(s) of action of corticosteroids to antagonise emesis. The 
data generated by the studies may provide information relevant to the design ofnovel 
anti-emetic therapies that can be rapidly pursued in man. At the very least, the 
studies should provide information relative to the rationale use of corticosteroids, as 







2.1 Cisplatin-Induced Emesis Studies 
2.1.1 Animals 
Albino or fitch ferrets (normal female and castrated male) weighing between 0.6-2.5 
kg were used for the cisplatin-induced emesis studies. They were obtained from a 
reputable breeder in Australia or New Zealand. They were housed in The Laboratory 
Animals Service Centre, The Chinese University of Hong Kong and maintained at 
1« 
21±l°C. Artificial lighting was provided with lights on between 06.00 h and 18.00 h. 
fT 
The artificial humidity was maintained at 50±5%. The animals had free access to 
commercially prepared dry pelleted diet (Laboratory Feline Diet 5003, The 
Richmand Standard, PMI® Nutrition International, St. Louis, U.S.A.) and water was 
available ad libitum. They were allowed 2 weeks to adapt to their new environment 
before being used in experiments. All experiments were approved by the Animal 
Research Ethics Committee, the Chinese University of Hong Kong (AREC Ref: 
97/003/ERG). 
2.1.2 Induction and Measurement of Emesis 
Ferrets were randomised and were transferred to observation cages (60 cm x 50 cm x 
60 cm) in the laboratory two days before starting the experiment. At 12.30 h, they 
were fed with approximately 95g of canned cat food (Whiskas®, Effem Foods Pty. 
Ltd., Malaysia). At 15.00 h, they were injected intraperitoneally with cisplatin 5 
mg/kg (t=0) to induce emesis. 
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To assess the anti-emetic potential of a drug treatment, the latency to the first retch or 
vomit, the total number of retches, vomits and episodes of retching/ or vomiting for 
72 h post cisplatin administration were calculated. Episodes of emesis were 
characterised by rhythmic abdominal contractions which are either associated with 
the oral expulsion of solid or liquid material from the gastrointestinal tract (i.e., 
vomiting) or not associated with the passage of material (i.e., retching movements). 
Episodes of retching and/ or vomiting were considered separate when an animal 
changed its location in the observation cage or when the interval between retches 
and/or vomits exceeded 5 sec. “ 
r 
Animal behaviour was recorded remotely by a video recording system. 4 video 
recorders (2 Panasonic NV-HD660 model and 2 Panasonic NV-F123 model, 
Panasonic, Japan) were used in conjunction with audio-video amplifiers (audio-video 
splitter, Toshiba VSP4, Maspro Denkoh Corporation, Japan) and 2 colour video 
cameras (a Sony CCD-TR 750E model and a Sony CCD-TRV81E model, Sony, 
Japan) to record the animal behaviour. In each recorder, the video signal was 
confirmed on a 14 inch television screen (Toshiba 1460XSH, Toshiba, Japan). The 
recorded experiment was played using a video player (Panasonic NV-HD660, 
Japan), which was connected to a 34 inch television (Toshiba 34E8DXC, Toshiba, 
Japan) (see Figure 2.1.1). 
A dry pellet diet (Laboratory Feline Diet 5003, The Richmand Standard, PMI® 
Nutrition International, St. Lois, U.S.A.) and water was available ad libitum 
throughout the 72 h period. 
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Figure 2.1.1 Sketch diagram of the closed circuit video recording system 
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2.1.3 The Effects of Corticosteroids on Cisplatin-Induced Acute and Delayed 
Retching and Vomiting 
Dexamethasone (0.1-1.0 mg/kg), betamethasone (0.3-3.0 mg/kg), 
methylprednisolone (1.0-10 mg/kg), hydrocortisone (1.0-30 mg/kg), fludrocortisone 
(1.0-10 mg/kg), or their respective vehicles were injected intraperitoneally 30 sec 
after cisplatin administration (5 mg/kg, i.p.). Corticosteroids or vehicle treatment 
was then continued at regular 8 h intervals for the duration of the experiment (see 
t« 
appendix I for formulations and corresponding vehicles). 
2.1.4 The Effects of Dexamethasone (1 mg/kg, i.p.) Administered as an 
Intervention Treatment on an Established Delayed Retching and Vomiting 
Response Induced by Cisplatin 一 
Animals were injected with cisplatin (5 mg/kg, i.p.) and were allowed to develop an 
acute emetic response. At 24 h post cisplatin injection the animals were 
administered dexamethasone 1 mg/kg, i.p. or vehicle (distilled water, 0.5 ml/kg). 
Drug or vehicle treatment was then continued at regular 8 h intervals for the 
remainder of the experiment. 
2.1.5 The Effects of Cortrosyn Depot (Tetracosactrin) on Cisplatin-Induced 
Acute and Delayed Retching and Vomiting 
The synthetic form of adrenocorticotrophic hormone, cortrosyn depot (tetracosactrin, 
ACTH 1-24) (0.1 mg/kg), or vehicle, was administered intramuscularly 4 h prior to 
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the injection of cisplatin (5 mg/kg, i.p.). Drug or vehicle administration was then 
repeated at 8, 20, 32，44, 56, 68 h post cisplatin injection. 
2.1.6 The Effects of Metyrapone on Cisplatin-Induced Acute and Delayed 
Retching and Vomiting 
The corticosteroid synthesis inhibitor (11-p-hydroxylase inhibitor), metyrapone (3.0-
10 mg/kg) or vehicle, was administered intraperitoneally 4 h prior to the injection of 
cisplatin (5 mg/kg, i.p). Metyrapone or vehicle administration was then repeated at 
30 sec, and then at regular 8 h intervals post cisplatin injection, for the duration of 
the experiment. 
% 
2.1.7 The Effects of Indomethacin on Cisplatin-Induced Acute and Delayed 
Retching and Vomiting 
The non-selective cycloxygenase (COX) inhibitor, indomethacin (3.0-30 mg/^g) or 
vehicle, was injected intraperitonelly 30 sec after cisplatin (5 mg/kg, i.p.) 
administration (t=0). Indomethacin or vehicle treatment was then continued at 
regular 8 h intervals up to 72 h. 
2.1.8 The Effects of DFU and L-745,337 Administered as an Intervention 
Treatments on an Established Delayed Retching and Vomiting Response 
Induced by Cisplatin 
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Animals were injected with cisplatin (5 mg/kg, i.p.) and were allowed to develop an 
acute emetic response. At 40 and 48 h post cisplatin injection, the animals were 
injected with selective cycloxygenase-2 inhibitors, DFU (1.0-10 mg/kg, i.p.) or L-
745,337 (10 mg/kg, i.p.), or their respective vehicles. 
2.1.9 The Effects of MK-886 (L-663,536) on Cisplatin-induced Acute and 
Delayed Retching and Vomiting 
»黍 
The selective 5-lipoxygenase activating protein (FLAP) inhibitor, MK-886 (1.0-10 
mg/kg) or vehicle was injected intraperitoneally 30 sec after cisplatin (5 mg/kg, i.p.) 
administration. Drug or vehicle treatment was then continued at regular 8 h intervals 
up to 72 h. � 
2.1.10 The Effects of a Combination of Indomethacin and MK-886 on Cisplatin-
Induced Acute and Delayed Retching and Vomiting 
Indomethacin (10 mg/kg) or vehicle and/or MK-886 (10 mg/kg) or vehicle were 
injected intraperitoneally 30 sec after cisplatin (5 mg/kg, i.p.) administration. Drug 
and/or vehicle combinations were continued at regular 8 h intervals for the duration 
of the experiment. The doses of indomethacin and MK-886 that were used in the 
combination study were selected from the initial single agent studies. 
Dexamethasone (1 mg/kg, i.p.) was also administered in the studies following the 
same dosing protocol as indomethacin and MK-886. It was included in the study as 
a positive control to inhibit emesis. 
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2.1.11 Statistical Analysis 
In each animal the latency to retch and/or vomit and the total number of retches, 
vomits and episodes was calculated in each one hour period for the duration of the 
experiment. The significance of difference between treatments was assessed by a 
one- or two-way analysis of variance (ANOVA) followed by a Fisher's Protected 
Least Significant Difference (PLSD) test or by an unpaired Student's t-test, as 
appropriate. Differences were considered significant when P < 0.05. IDgo values 
1« 
were determined on the mean data by non-linear regression analysis 
(KaleidaGraphTM, Synergy Software, U.S.A.). 
% 
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2.2 Motion-Induced Emesis Studies 
2.2.1 Animals 
Suncus murinus (house musk shrew) of either sex (female 25-48; male 39-83 g) were 
used in the motion-induced emesis studies. The breeding colony ancestors were 
originally from Taipei and developed at the Central Institute for Experimental 
M 
Animals Kanagawa，Japan. Breeding pairs were brought to Hong Kong in 1995 and 
housed in The Laboratory Animals Service Centre, The Chinese University of Hong 
Kong, at 23-25^C under artificial lighting (lights on between 06.00 h and 18.00 h). 
The artificial humidity was maintained at 50±5o/o. They had free access to a � 
commercially prepared dry pelleted diet (Laboratory Feline Diet 5003, The 
Richmand Standard, PMI® Nutrition International, USA) and water was available ad 
libitum. All experiments were approved by the Animal Research Ethics Committee, 
The Chinese University ofHong Kong (AREC Ref: 97/003/ERG). 
2.2.2 Measurement of Emesis 
Episodes of emesis were characterised by rhythmic abdominal contractions that were 
either associated with the oral expulsion of solid or liquid material from the 
gastrointestinal tract (i.e. vomiting) or not associated with the passage of material 
(i.e. retching movements). Episodes of retching and/or vomiting (bouts) were 
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considered separate when an animal changed its location in the observation chamber, 
or when the interval between retches and/or vomits exceeded 2 sec. 
2.2.3 Induction of Emesis in Motion-Naive Suncus murinus: Effects of 
Glucocorticoids 
All animals were fasted for at least 6 h prior to experimentation and were housed in 
groups of 6 or less. On the day of the experiment, the animals were fasted for at least 
6 h prior to experimentation and were fed with approximately 15 g of canned cat 
food (Whiskas®, Effem Foods Pty. Ltd., Malaysia). The feeding was performed in 
the Suncus murinus holding room to minimize stress to the animals. After feeding, 
the animals were transferred to the laboratory 30 min after feeding and injected � 
intraperitoneally with dexamethasone (0.01-1.0 mg/kg), betamethasone (0.03-3.0 
mg/kg), methylprednisolone (0.3-30 mg/kg), or their respective vehicles (distilled 
water; 2 ml/kg). 60 min later, they were transferred to clear Perspex observation 
chambers (21 x 14 x 13 cm) on a linear reciprocating horizontal shaker (LabPlant 
Heidolph Promax 2020). They were then exposed to motion (4 cm horizontal 
displacement at 1 Hz) for 5 min and observed for the production of retching and/or 
vomiting. Control animals were placed in the observation chambers for 5 min urider 
stationary conditions (Stationary Controls). All of the animals were immediately (at 
65 min post drug or vehicle treatment) removed from the observation chamber and 
decapitated to obtain blood samples (see Figure 2.2.1). 
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2.2.4 Induction of Emesis in Motion-Sensitive Suncus murinus: Effects of 
Dexamethasone 
All animals, housed in groups of 6 or less, were fasted for at least 6 h prior to 
experimentation. On the day of the first test, the animals were fed with 
approximately 15 g of canned cat food (Whiskas®, Effem Foods Pty. Ltd., Malaysia) 
in the animal holding room to minimise stress to the animals. After 30 min, the 
animals were transferred to the laboratory and injected intraperitoneally with distilled 
water (2 ml/kg). They were then exposed to motion (Initial Test; 4 cm horizontal 
displacement at 1 Hz) for 5 min and observed for the production of retching and/or 
vomiting. Animals failing to exhibit > 2 episodes of retching and vomiting were 
excluded from further investigation. The motion-sensitive animals were then � 
'earmarked' using a hole-punch to enable subsequent identification. They were then 
returned to their home cages in the holding room where they had free access to food 
and water was available ad libitum. 
The testing sequence was repeated in the motion-sensitive animals exactly 14 days 
later. Thus, the motion-sensitive animals were fasted for at least 6 h prior to being 
presented with approximately 15 g of canned cat food. They were then randomised 
to receive an intraperitoneal injection of dexamethasone (0.01-1.0 mg/kg) or vehicle. 
60 min later, the animals were re-exposed to motion (4 cm horizontal displacement at 
1 Hz) for 5 min. Control animals were placed in the observation chambers for 5 min 
under stationary conditions (Stationary Controls). They were a population of Suncus 
murinus that previously exhibited > 2 emetic episodes following an initial motion (4 
cm horizontal displacement at lHz for 5 min) challenge. They were then 
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immediately (at 65 min post drug or vehicle treatment) removed from the 
observation chamber and decapitated to obtain blood samples (see Figure 2.2.2). 
Figure 2.2.2 Protocol used for the induction of emesis in motion-sensitive Suncus 
murinus 
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2.2.5 Preparation of Serum 
Approximately 1 ml of blood was collected into 1.5 ml polypropylene tubes 
following decapitation of Suncus murinus. The blood was stored at 4±2°C and then 
centrifuged at room temperature for 10 min at 9,000 g before the end of the day 
(micro-centaur centrifuge, MSE-41137-2182, England). The resultant supernatant 
(serum) was collected and stored at -70°C until assay for cortisol and ACTH. 
1« 
� 
2.2.6 Measurement ofSerum Cortisol by Enzyme-Linked Immunoassay (ELISA) 
2.2.6.1 Immunoassay kit 
> 
A commercially available enzyme-linked immunoassay -(ELISA) kit (DSL-10-2000 
ActiveTM Cortisol Enzyme Immunoassay Kit, Diagnostic Systems Laboratories Inc., 
Webster, Texas, U.S.A.) was used to determine serum cortisol levels. The assay 
follows the basic principle where there is competition between an unlabeled antigen 
and an enzyme labeled antigen for a fixed number of antibody binding sites. The 
amount of enzyme-labeled antigen bound to the antibody is inversely proportional to 
the concentration of analyte present after separation of unbound material. All the 
corticosteroids tested were free from cross-reactivity. Other performance 
characteristics including sensitivity, precision, recovery linearity and specificity were 
as specified in the kit. 
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2.2.6.2 Assay procedures 
The serum samples were defrosted at room temperature and centrifuged at 9,000 g 
for 1 min. 25 i^l of the resultant supernatant or cortisol standards (0-60 fig/dl) was 
added to the kits incubation wells. 100 i^l of the enzyme conjugate solution (a 
solution of cortisol conjugated to horseradish peroxidase in a protein-based buffer) 
was added and the wells were mixed by gently tapping. Each incubation well was 
coated with goat anti-rabbit globulin serum. 100 i^l of cortisol antiserum were then 
“ 
added to the well and incubated for 45 min at room temperature on a shaking 
f< 
platform (HAAKE SWB 20, HAAKE Mess-TechnikGmbHu Co., Germany). The 
reaction mixture was aspirated and the wells were washed 5 times with washing 
solution (buffered saline). The wells were inverted and blot dried on absorbent paper 
、 
then 100 i^l of tetramethylbenzidine (TMB) citrate buffer was added. The wells were 
further incubated for 15 min at room temperature on a shaking platform (HAAKE 
SWB 20, HAAKE Mess-TechnikGmbHu Co., Germany) before stopping the 
reaction with 100 i^l 0.2 M sulphuric acid. A cortisol control standard curve (0-60 
^g/dl) was constructed during the assay and cortisol controls (supplied in the kit) 
were also assayed (see Figure 2.2.3). 
The absorbance of the contents of the wells were read at 450 nm using a ELISA Plate 
Reader (MAXline Microplate Reader, VMAX, Molecular Device Corporation, 
California). A standard 1-site competition curve was constructed by non-linear 
TTNyf 
regression analysis (Prism, GraphPad , GraphPad Software, U.S.A.) to determine 
the cortisol levels in the serum sample; data was compared to the cortisol standards 
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supplied in the analytical kit (see Figure 2.2.4 for an example of a standard cortisol 
curve). 
Figure 2.2.3 Protocol used to measure serum cortisol by enzyme-linked 
immunoassay 
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Figure 2.2.4 An example of a cortisol standard curve 
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The curve was fitted as a 1-site competition non-linear regression curve using the 
GraphPad Prism program with equation: 
Y = Bottom + (Top-Bottom)/(l+10A(X-LogEC50)); where 
% 
X = log(concentration); Y = absorbance (450nm) 
2.2.7 Measurement of Serum Adrenocorticotrophin (ACTH) by 
Radioimmunoassay (RIA ) 
2.2.7.1 Immunoassay kit 
A commercially available radioimmunoassay (RIA) kit (ICN-07-106101, ICV 
Biomedicals, Inc., Diagnostic Division, ICN Pharmaceutical, Inc., U.S.A.) was used 
for the determination of serum ACTH levels. In the assay, a limited amount of 
antibody was reacted with its antigen (i.e. ACTH in the serum) to form an antigen-
antibody complex. The addition of more antigen labeled with '^ ^1 competes with the 
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non-labeled antigen for binding sites on the antibody. A fixed concentration of ['^^I]-
antigen was used in the assay. After equilibration, the antibody bound ['^^I]-antigen 
was separated from the unbound [^^^I]-antigen by precipitation. The precipitate was 
then assayed for ⑵！ using a gamma counter. Dexamethasone, betamethasone and 
methylprednisolone had no cross-reactivity when tested at concentrations that were 
33 times higher than the predicated concentrations in the plasma (assuming 100% 
bioavaliability following administration). The performance characteristics including 
specificity and accuracy were as specified in the kit. 
1« 
/f 
2.2.7.2 Assay procedures 
The plasma samples were defrosted at 4±20C and centrifuged at 9,000 g for 1 min to � 
dispose of fibrin. All the lyophilized reagents (standards- and controls provided in the 
kit) were reconstituted prior to assay and were left to stand at 4±2�C for 15 min. The 
samples and reagents were kept at 4±2°C throughout the experiment. 
50 i^l of serum or hACTH standards (0-748 pg/ml) was pipetted to corresponding 
labeled polystyrene test tubes, held in a test tube rack. They were placed inside an 
iced-water bath to maintain the temperature at approximately 4±2°C. 100 ^1 of anti-
serum, or diluent water in 0 pg/ml standard, and hACTH"'^^ (approximately 0.0073 
^iCi) was added respectively to each tube. Each tube was shaken for 30 sec and then 
vortexed (super-mixer 1291, Lab-line instruments, Inc, U.S.A.). The tubes were 
covered with aluminum foil and incubated for at least 16 h at 4±2°C in the fridge 
After incubation, 0.5 ml of precipitant solution (a solution o f P E G antibody with goat 
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anti-rabbit gamma globulins in a 0.01 M phosphosaline buffer) was added. Each 
tube was covered with parafilm®. They were mixed for 30 sec and then vortexed 
thoroughly until one homogenous color was seen. They were then centrifuged at 
1，000 g (J6-M1, Backman Instruments, Inc., California) for 15 min at 6 � C . The tubes 
were turned upside-down and were tapped. The supernatant was decanted and the 
rims of the test tubes were blotted dry on absorbent paper before turning upright. 
The tubes were covered with parafilm® and placed into racks in a gamma counter 
(Packard CoBra^^ II，Packard Instrument Co., U.S.A.) at room temperature. The 
»i 
radioactivity of the precipitate remaining in the tubes was quantified using a counting 
time o f 2 min per tube (see Figure 2.2.5). 
An ACTH standard curve (0-748 pg/ml) (% bound versus the concentration of 
ACTH) was constructed and ACTH controls (supplied in the kit) were also assayed 
using the following formula. 
% B / B o = { [ C P M ( s a _ e ) — C P M (b,ank, NSB)]丨 
[CPM (Ostandard)-CPM (blank,NSB)])x 100； wherC 
CPM = counts per minute 
Sample = particular sample or standard being calculated 
0 Standard = 0 tube (also known as 100% binding tube) 
NSB = non specific binding 
A standard sigmoidal curve was constructed by non-linear regression analysis 
(Prism, GraphPad™, GraphPad Software, U.S.A.) to determine the ACTH levels in 
the serum samples; data was compared to the ACTH control standards supplied in 
the analytical kit (see Figure 2.2.6 for an example of an ACTH standard curve). 
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Figure 2.2.5 Procedure for the measurement of serum ACTH by 
radioimmunoassay 
/
50 pil of Senim / Standard / Control 
Add: 100 n-l Anti-Serum / Diluent Water 
100 叫[I'"]-h-ACTH 
Iced Water Bath Containing _ _ 
Polystyrene Test Tubes ；^  7 � : : ~ . “ 
~~~~^ ,,-,: -.' -' • •'". '-•.• I、，.V_>^ ‘ ^ \ \^' "V>^ ' ^^. _. 
I , ' . ^ , . i ' ? ^ ' . ' . , . . ' . ~ ' . , . , . . • • ‘ . 
” 
II 
^ K ^ H ^ f f ^ E ^ l a ^ Shake by handfor 30 
'/；::萝;';^  ;； W；-^ .-^；.'； sec and Vortex to Mix 
Cover with Aluminium 
，r FoU Lid 
Aluminium Foil Lid | j 
Licubate Samples for 16 h 
TT 7 J 7 r T ^ a t 4 ± 2 ' C 
mm^m 
/
Add 0.5 ml Precipitant Solution 
Thcn Cover With Parafilm® and � 
Vortex for 30 Sec to Mix 
I""^p ~^p ~^p -^"^p ~^~p 
d _ 7 �了 : - ~ ‘ 
: • - ( _ : 、 : • : : 、 • 、 : / 
! . ., •.广."，•，‘’，."、'，•• . , ""’•’ 
Centrifuge Samples for 15 min 
yj at l , 0 0 0 g a t 4 ± 2 ' C 
rrr- *r n r- 了 T ： •:. •、 '. '： “ :二 。 . 一 一 . 一 、 一 ， 、 一 X . ' ' 
">y:y::^:y:r;.^: 
Discard Supematant That Contains 
¥ Unbound Labeled Antigen 
门 r i f"P 0 n Then Cover With Parafim® 
，' 
Count Antibody Bound 
Labeled ['"^-Antigen in 
Resulting Precipitation Using 
Gamma Counter 
-. 78 
Figure 2.2.6 An example of an ACTH standard curve 
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The curve was fitted by non-linear regression using Prism program with equation: 
Y=Bottom + (Top-Bottom)/( 1+1 O^((LogEC50-X))); where 
X = log (concentration) and 
Y = % binding, which starts at Bottom and goes to Top with a sigmoid shape. 
2.2.8 Statistical Analysis 
For the motion-induced emesis experiments in naive animals, the data was analysed 
by a one-way ANOVA followed by Fisher's Protected Least Significant Difference 
(PLSD) test (Statsview®, Abacus Concepts, U.S.A.). To assess the effects of 
glucocorticoids in the screened animals, the data was subjected to analysis by a 
repeated measures two-factor ANOVA with comparisons of specified means by Pre-
Planned Contrasts (Super-ANOVA®，Abacus Concepts, U.S.A.). 
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For the blood hormone levels assays, the correlation between cortisol and ACTH 
levels was analysed by Fisher's r to z test (Statview®, Abacus Concepts, U.S.A.). A 
two-factor ANOVA with comparisons of specified means by Planned Contrasts was 
used to compare the effects of cortisol or ACTH in normal and motion-challenged 
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3.1 Cisplatin-Induced Emesis 
3.1.1 General Profile of Emesis Induced by Cisplatin 
The investigations used castrated male and normal female animals but each 
experiment had a balanced design, were appropriate. The experiments were not 
designed to directly compare castrated male and normal female responses to 
cisplatin. However, pooling of the control data from the experiments utilising 
|i 
distilled water as the vehicle (9 male, 9 female), did not reveal statistically significant 
differences in the total numbers of episodes (male 69.1士12.5, female 82.5士9.2)， 
retches (male 345.5±70.5，female 443.6士65.8) or vomits (male 34.2士7.3, female 
40.3士3.7) or the latency to onset of emesis (male 13.6土5.6 h, female 10.0士4.6 h) � 
induced by cisplatin (P>0.05) (see Figure 3.1). 
3.1.2 Antagonism of Cisplatin-Induced Emesis by Corticosteroids 
The profile of cisplatin-induced acute and delayed emesis and the effect of 
dexamethasone (0.1-1 mg/kg, i.p.) are shown in Figure 3.2. In the vehicle treated 
animals, cisplatin induced emesis within 4.4土1.2 h and there were 84.3士32.7 retches 
+ vomits on day 1，182.7士66.8 retches + vomits on day 2 and 142.7土50.1 retches + 
vomits on day 3. The profile of emesis occurring on days 2 and 3 was representative 
of the emesis that occurred in the other experiments involving betamethasone where 
the control animals received distilled water as vehicle and cisplatin (Figure 3.3). 
However, some of the control animals in experiments involving the use of 
methylprednisolone (Figure 3.4) and hydrocortisone (Figure 3.5) failed to develop a 
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strong retching + vomiting response during the initial 24 h period and the effect of 
drug treatment could not be assessed. In the group of animals that received 
molecusol (2 ml/kg) as the vehicle control for fludrocortisone, there were 121.3±50.4 
retches + vomits on day 1, 55.0±49.5 retches + vomits on day 2 and 250.5±48.4 
retches + vomits on day 3; the latency to onset of cisplatin-induced emesis was 
14.1±13.3 h (see Figure 3.6 for profile). 
Dexamethasone produced dose-related antagonism of the emesis occurring during 
it 
the initial 0-24 h period (Figures 3.2 and 3.7). The maximum inhibition observed was 
/f 
64.0 % at 0.3 mg/kg (P>0.05). Betamethasone also caused a dose-related antagonism 
of the retching + vomiting during the initial 24 h period and a similar 71.1 % 
reduction was seen at 0.3 mg/kg (P>0.05); increasing the dose to 3 mg/kg � 
antagonised emesis by 99.5 % (P<0.05; Figures 3.3 and 3.7). No dose-related 
antagonism was observed with fludrocortisone (Figures 3.6 and 3.7). All drugs tested 
except fludrocortisone caused an apparent dose dependent increase in the latency to 
onset of cisplatin-induced retching + vomiting (Figures 3.8). Betamethasone 
appeared to be the most potent corticosteroid to delay the onset of retching + 
vomiting (Figure 3.8). 
Examining the effect of dexamethasone on the profile of cisplatin-induced emesis 
occurring during the remaining 2 day period revealed that emesis could be practically 
abolished in a dose-related manner up to 56 h following cisplatin administration 
(maximum reduction in the 24-56 h period was 96.7 % at 1 mg/kg; P<0.05; see 
Figures 3.2 and 3.7). The protective effect during the 24-56 h period was also shared 
by betamethasone (maximum reduction was 99.0 % at 3 mg/kg; P<0.05; Figures 3 3 
83 
and 3.7)，methylprednisolone (maximum reduction was 98.9 % at 10 mg/kg; P<0.05; 
Figures 3.4 and 3.7), hydrocortisone (maximum reduction was 66.6 % at 30 mg/kg; 
尸>0.05; Figures 3.5 and 3.7) and fludrocortisone (maximum reduction was 86.9 % at 
10 mg/kg: P<0.05; Figures 3.6 and 3.7). Analysis of the data revealed the following 
rank order of anti-emetic potency to reduce the 24-56 h retching + vomiting response 
(approximate IDgo values are shown): betamethasone (IDgo < 0.3 mg/kg) > 
dexamethasone (IDgo -0.3 mg/kg) > methylprednisolone (IDgo « 0.7 mg/kg) > 
fludrocortisone (IDgo « 1.9 mg/kg) > hydrocortisone (IDgo >30 mg/kg). The IDgo 
1» 
value for betamethasone could not be extrapolated but is less than 0.3 mg/kg. Only 
广 
fludrocortisone was effective to reduce the retching + vomiting response occurring 
after the 56 h period (3 mg/kg reduced retching + vomiting by 76.1 %; P<0.05; 
Figures 3.6 and 3.7). 
% 
3.1.3 The Effect of Dexamethasone (1 mg/kg，i.p.) Administered as an 
Intervention Treatment on an Established Delayed Retching and Vomiting 
Response Induced by Cisplatin 
Ferrets were randomised to receive 8 hourly administrations of dexamethasone (1 
mg/kg, i.p.) or distilled water (0.5 ml/kg, i.p.) starting 24 h post the injection of 
cisplatin. In the groups receiving cisplatin and distilled water there were 70.8±47.1, 
353.3il44.1 and 88.5±16.7 retches + vomits during the 0-24, 24-56 and 56-72 h 
periods respectively (see Figure 3.9). The latency of cisplatin to induce emesis and 
the numbers of retches + vomits occurring in the 0-24 h period of the dexamethasone 
group (latency = 7.2±1.7 h, retches + vomits = 136.5±57.6) was not statistically 
different (P>0.05) from the control animals (latency = 8.8士2.5 h, retches + vomits = 
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70.8i47.1). In the 24-56 h period, dexamethasone produced a 63.1 % reduction in 
retching + vomiting but potentiated the retching + vomiting response by 47.5 % in 
the 56-72 h period. However, the changes did not achieve statistical significance 
(P>0.05). 
3'1'4 The Effect ofCortrosyn Depot (Tetracosactrin) on Cisplatin-Induced Acute 
and Delayed Retching and Vomiting 
I* 
In vehicle treated animals, cisplatin induced emesis following a latency 9.0土5.8 h 
and comprised 208.3±91.0 retches + vomits on day 1，179.5土69.4 retches + vomits 
on day 2 and 253.3士96.6 retches + vomits on day 3 (see Figures 3.10.0 and 3.10.1). 
The synthetic adrenocorticotrophin hormone, cortrosyn (0.1 mg/kg, i.m.), completely � 
prevented retching + vomiting in 4 out of 4 animals during the first day of 
administration (P>0.05). Indeed, only 2 out of 4 animals exhibited retches or vomits 
during the entire 72 h observation period (individual latencies were 44.9 h and 57.4 
h). Consequently, the numbers of retches + vomits occurring during the entire 72 h 
period was reduced significantly by 90.65 % (P<0.05). A more focused analysis 
revealed a significant 87.7 % reduction of retching + vomiting during the 
glucocorticoid sensitive 24-56 h period (P<0.05). There was also a 81.6% reduction 
of retching + vomiting during the 56-72 h period but the reduction was not 
statistically significant (P>0.05). 
SJ.5 The Effect of Metyrapone on Cisplatin-Induced Acute and Delayed 
Retching and Vomiting 
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In vehicle treated animals, cisplatin induced emesis following a latency of 5.1士0.7 h 
and comprised 67.0±15.0 retches + vomits on day 1, 216.4士76.4 retches + vomits on 
day 2 and 244.0±30.3 on day 3 (Figures 3.11.0 and 3.11.1). The repeated 
administration of metyrapone at 10 and 30 mg/kg did not prevent emesis in any of 
the animals {P>0.05) and failed to affect significantly (P>0.05) the onset of retching 
+ vomiting when compared to the control animals. However, in the 0-24 h period, 
metyrapone dose-dependently potentiated the numbers of retches + vomits; the 
maximum increase observed was 275.3 % at 30 mg/kg (P<0.05). Conversely, there 
I* 
was a weak trend for metyrapone to reduce emesis during the 24-48 and 48-72 h 
period but none of the reductions were statistically significant (P>0.05). The 
retching + vomiting occurring during the glucocorticoid sensitive 24-56 h period was 
not significantly affected by metyrapone (P>0.05). A higher dose ofmetyrapone 100 
mg/kg was utilised in 2 animal but the data was not reported since the ferrets died 
during the experiment. 
3.h6 The Effect oflndomethacin，DFU and L-745,337 on Cisplatin-induced 
Acute and Delayed Retching and Vomiting 
In animals that received cisplatin and the vehicle for indomethacin (i.e/ 10% 
NaHCO3), there were 78.0士37.1 retches + vomits on day 1’ 112.±53.2 retches + 
vomits on day 2 and 140.0土62.4 retches + vomits on day 3; the latency to onset of 
retching and/or vomiting was 5.7士2.5 h (Figures 3.12.0 and 3.12.1). Indomethacin at 
30 mg/kg, administered three times per day, potentiated significantly the retching + 
vomiting response during 0-24 h period by 127.9 % (P<0.05). Indomethacin at 3 
mg/kg potentiated significantly the retching + vomiting response occurring during 
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the 24-48 h (P<0.05) but did not affect significantly the retching + vomiting response 
at any dose occurring during 48-72 h period (P>0.05). 
Studies investigating the anti-emetic potential of DFU used with a different approach 
since the drug was difficult to solubulise. The vehicle used for the studies was 60% 
PEG 200 and only 2 administrations were performed to minimise toxicity. Thus, 
vehicle or DFU was administered at 40 h and 48 h post injection of cisplatin (i.e. 
after the animals had developed retching and/or vomiting) since the previous studies 
i( 
in this thesis had identified the phase to be sensitive to corticosteroids. 
产 
In the animals that were randomised to receive vehicle following cisplatin 
administration there were 134.2+59.6 retches + vomits during the 0-40 h observation 
、 
period; the latency to onset of retching and /or vomiting was 15.8士8.6 h (Figures 
3.12.2 and 3.12.3). The DFU treatment groups exhibited 255.0±93.3, 68.6±27.4 and 
144.4i58.9 retches + vomits during the 0-40 h observation period, respectively, prior 
to the administration of 1, 3 and 10 mg/kg DFU. The differences in magnitude of 
retching +vomiting or the latencies to onset of retching + vomiting were not 
statistically different from the vehicle control animals (P>0.05). 
A similar treatment regimen was used to investigate the anti-emetic potential of L_ 
745,337, where 2 drug administrations were given at 40 and 48 h. Thus, in the 
animals that were randomised to receive the cisplatin and the vehicle (i.e. 25 % 
molecusol) there were 323.0±90.8 retches + vomits during the 0-40 h observation 
period; the latency to onset of retching and /or vomiting was 10.0士8.3 h (Figures 
3.12.4 and 3.12.5). The L-745,337 10 mg/kg treatment group exhibited 214.8土65.1 
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retches + vomits during the 0-40 h observation period, prior to the administration of 
L-745,337; the differences in magnitude of retching + vomiting or the latencies to 
onset ofretching + vomiting were not statistically different from the vehicle control 
animals (P>0.05). 
There was no significant difference between the retching + vomiting response of the 
vehicle treated and DFU treated animals during the 40-48 h period. However, DFU 
reduced the retching + vomiting response during the 48-56 h period (control treated 
1» 
animals exhibited 160.0±50.6 retches + vomits) by 52.2 % (P>0.05) , 71.7 % 
产 
(P<0.05) and 68.5 % (P<0.05) respectively at 1, 3，and 10 mg/kg (see Figures 3.12.3 
and 3.12.4). Conversely, L-745,337 had no action to modify retching + vomiting 
compared to the respective control vehicle treated animals during the 40-48 (P>0.05) 
% 
or 48-56 h period (P>0.05; see Figures 3.12.5 and 3.12.6). 
For comparative purposes, the anti-emetic potential of indomethacin during the 40-
48 and 48-56 h periods was analysed (data from Figure 3.12.0). However, 
indomethacin significantly potentiated the retching + vomiting response at 3 mg/kg 
during these time periods (P<0.05). A ferret treated with indomethacin at 30 mg/kg 
died during the experiment. 
J . / . 7 The Effect ofMK-886 on Cisplatin-Induced Acute and Delayed Retching 
and Vomiting 
In vehicle treated animals, cisplatin induced emesis following a latency of 14.0士8 7 
h. The response comprised 71.6士46.6 retches + vomits on day 1, 48.8±48.8 retches 
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+ vomits on day 2 and 179.4±53.3 retches + vomits on day 3 (Figures 3.13.0 and 
3.13.1). The highest dose of MK-886 10 mg/kg shortened the latency to onset of 
emesis by approximately 2.7 h (P>0.05) but none of the doses tested (1-10 mg/kg) 
significantly affected the retching + vomiting response during the 0-24 or 24-48 h 
period (P>0.05). There was a trend for a reduction of vomiting during the 48-72 h 
period (maximum reduction seen was 67.8 %) but this was not statistically 
significant (P>0.05). MK-886 failed to produce a dose-related inhibition ofretching 
+ vomiting during the glucocorticoid sensitive (24-56 h) phase (P>0.05) but did 
1« 
produce a non-significant trend to reduce emesis during the 56-72 h period (P>0.05). 
产 
A ferret treated with MK-886 at 3 mg/kg died during the experiment. 
3.1.8 The Effect of Combination of Indomethacin and MK-886 on Cisplatin- � 
Induced Acute and Delayed Retching and Vomiting 
The experiment was intended to compare the anti-emetic potential of a combination 
of indomethacin and MK-886 with that of dexamethasone. The control animals 
received cisplatin and combinations of respective vehicles (i.e. 25 % molecusol for 
MK-886 and 10% NaHCO3 for indomethacin and dexamethasone). The individual 
doses ofMK-886, indomethacin and dexamethasone were selected from the previous 
studies presented in this thesis. 
In the control vehicle/vehicle cisplatin treated animals there were 169.5土59.0 retches 
+ vomits on day 1，143.0±47.9 retches + vomits on day 2 and 53.3±36.6 retches + 
vomits on day 3 (Figures 3.14.0 and 3.14.1). The latency for cisplatin to induce 
emesis was 2.9±0.7 h. 
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The repeated treatment of indomethacin 10 mg/kg failed to modify cisplatin-induced 
retching + vomiting (P>0.05). Similarly, MK-886 10 mg/kg also failed to antagonise 
cisplatin-induced retching + vomiting although there was a non-significant reduction 
of60.8 % and 57.9 % during the 0-24 and 24-56 h period respectively (P>0.05). The 
combination treatment of indomethacin 10 mg/kg and MK-886 10 mg/kg shortened 
the latency to onset of emesis by approximately 2.8 h {P>0.05) and significantly 
potentiated the retching + vomiting response in the 24-48 h period by 377.0 % 
(P<0.05). There was also a significant 391.9 % increase in retching + vomiting 
during the 24-56 h period (P<0.05). “ 
产 
Dexamethasone 1 mg/kg prevented retching + vomiting in 1 out of 4 ferrets 
completely and significantly reduced the retching + vomiting occurring during the 0-
、 
72 h period by 78.1 % (P<0.05; control group retches + vomits = 365.8±110.3). 
There were also 69.9, 86.4, 84.6 and 76.2 % reductions respectively during the 0-24, 
24-48, 48-72 and 24-56 h periods but these reductions failed to achieve statistical 
significant (P>0.05). A ferret treated with the combination of indomethacin and 
MK-886 died during the experiment. 
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3.2 Motion-Induced Emesis 
3.2.1 General Effect ofMotion on Serum Cortisol and ACTH Levels in Motion 
Naive Suncus murinus 
These studies used animals that had no prior exposure to motion (i.e. motion naive) 
and followed a protocol similar to Javid & Naylor (1999). Animals were randomised 
•* 
to receive vehicle or drug administration in several experiments. 18 out o f 2 1 male 
ff 
and 28 out of30 female animals that received vehicle, and acted as controls, vomited 
on exposure to the motion stimulus. The female animals exhibited more episodes 
(male 2.5i0.6, female 5.6±0.7; P<0.05) of retching (male 9.0il .9, female 20.6i2.5; 
% 
P<0.05) and vomiting (male 1.1±0.3, female 3.5±0.5; P<0.05) than the male animals. 
However, there was no difference in the latency of onset ofretching and or vomiting 
(male 3.0i0.3 min, female 2.7±0.2 min; P>0.05). Generally speaking, the cortisol 
and ACTH levels of control animals that received vehicle and remained stationary 
were not significantly different between the sexes (cortisol levels: male 3.0土0.8 ^ig/dl 
(n=19), female: 3.6t0.6 ^ig/dl (n=25), P>0.05; ACTH levels: male 704.1±301.8 
pg/ml (n=20), female 536.6+161.1 pg/ml, (n=30); P>0.05). ‘ 
However, in female animals, the numbers of emetic episodes (P<0.05), retches 
(P<0.05) and vomits (P<0.05) was positively correlated to ACTH levels measured 
after the motion stimulus (Figure 3.15). No significant correlation was evident 
between cortisol levels and the emetic parameters of either sex (data not shown). 
However, in the remainder of the thesis, only data collected on the numbers of 
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episodes has been reported, since there is controversy on the accuracy of recording 
individual retching responses in this species (Andrews et al., 1996). 
3.2.2 The Effect of Glucocorticoids on Motion-Induced Emesis and Cortisol and 
ACTHLevels in Motion-Naive Male Suncus murinus 
Experiments were conducted to establish the potential anti-emetic action of 
dexamethasone (0.01-1 mg/kg), betamethasone (O.Q3-3 mg/kg) and 
methylprednisolone (0.3-30 mg/kg) in male and female animals. 
3.2.2.1 Effect of dexamethasone 
In the experiments involving the use of dexamethasone, only 4 out of 7 control 
animals exhibited episodes of retching and/or vomiting (latency in responding 
animals was 3.6i0.7 min; see Figure 3.16A). Dexamethasone failed in these 
experiments to antagonise motion-induced emesis (P>0.05; Figure 3.16B). At the 
end of the motion test, there was a trend for an elevation in cortisol (stationary 
controls 2.8±1.5 ^g/dl, provocative motion challenged controls 6.1i2.3 ^g/dl) and 
ACTH levels (stationary controls 644.0±450.9 pg/ml, provocative motion challenged 
controls 1608.3±1112.0 pg/ml), but none of the changes were statistically significant, 
(P>0.05; see Figure 3.16C and Figure 3.16D). Dexamethasone had no action to 
modify cortisol or ACTH levels in stationary control animals or in the provocative 
motion challenged animals (P>0.05; see Figure 3.16D). 
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3.2.2.2 Effect of betamethasone 
All vehicle treated control animals (7 out of 7) exhibited episodes of retching and/or 
vomiting following exposure to motion (Figure 3.17A). Motion also induced an 81.0 
o/o increase in cortisol levels in vehicle treated group (stationary controls 4.2土1.5 
^g/dl, provocative motion challenged animals 7.6±2.0 ^g/dl, P<0.05; Figure 3.17C). 
The motion-induced increase in cortisol was antagonised significantly by 
betamethasone (0.03-0.3 and 3 mg/kg; P<0.05; Figure 3.17C). However, 
I* 
betamethasone failed to antagonise motion-induced emesis (P>0.05; Figure 3.17B). 
In addition, betamethasone had no action to modify cortisol or ACTH levels in the 
stationary controls (P>0.05; Figure 3.17C and Figure 3.17D). Motion failed to 
significantly modify serum ACTH levels (stationary controls 1224.3±711.8 pg/ml， 
% 
provocative motion challenged animals 2678.7±2300.9 pg/ml, P>0.05; Figure 
3.17D). 
3.2.2.3 Effect of methylprednisolone 
All vehicle-treated control animals (7 out of 7) exhibited episodes of retching and/or 
vomiting following exposure to motion (Figure 3.18A). Motion also induced a 238.8 
o/o increase in cortisol levels in vehicle-treated control animals (stationary controls 
4.5±1.6 ^ig/dl, provocative motion challenge 15.2±4.2 ^g/dl, P<0.05; Figure 3.18C) 
but failed to modify ACTH levels (P>0.05; Figure 3.18D). Methylprednisolone 
failed to modify motion-induced emesis (P>0.05; Figure 3.18B) but reduced 
significantly the motion-induced increase in cortisol levels at 0.3-10 mg/kg (P<0.05. 
一. 9 3 
Figure 3.18C). A higher dose of 30 mg/kg was ineffective to reduce the motion-
induced increase in cortisol levels. Methylprednisolone had no significant action to 
modify cortisol or ACTH levels in the stationary control animals (P>0.05). 
However, animals treated with 0.3 mg/kg methylprednisolone had a significant 
1979.4 % increase in ACTH levels following provocative motion (P<0.05; Figure 
3.18D). 
3.2J The Effect of Glucocorticoids on Motion-Induced Emesis and Cortisol and 
I* 
ACTH Levels in Motion Naive Female Suncus murinus 
3.2.3.1 Effect of dexamethasone 
All the vehicle control animals (12 out of 12)，that were exposed to provocative 
motion, exhibited episodes of retching and/or vomiting following a latency of 
2.8±0.3 min (Figure 3.19A). Dexamethasone at 0.01, 0.1 and 1 mg/kg antagonised 
significantly the number of episodes by 57.6 %, 68.5 % and 75.3 % respectively 
(P<0.05; control episodes 6.1土0.9; Figure 3.19B). However, dexamethasone had no 
effect on cortisol or ACTH levels in stationary controls (/^0.05; Figure 3.19C and 
3.19D). Surprisingly, however, dexamethasone at 0.3 and 0.1 mg/kg reduced 
significantly the cortisol and ACTH levels respectively by 321.7 % (P<0.5; Figure 
3.20C) and 204.6 % (P<0.05; Figure 3.20D) in animals that received the provocative 
motion when the values were compared to the paired control animals that remained 
stationary. 
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3.2.3.2 Effect of betamethasone 
All the vehicle control animals (9 out of 9), that were exposed to provocative motion 
exhibited episodes of retching and/or vomiting following a latency of2 .1±0.4 min 
(Figure 3.20A). Motion also induced a significant 270.0 % increase in cortisol levels 
o f t h e vehicle treated group (stationary controls 3.2l0.9 ^ig/dl, provocative motion 
challenged animals H .8 i3 .3 ^ig/dl; P<0.05; Figure 3.20C). The motion-induced 
increase in cortisol level was significantly antagonised by betamethasone at 0.03-3 
I* 
mg/kg (P<0.05; Figure 3.20C). However, there were still significant differences 
(P<0.05) in the cortisol levels of the stationary controls that received betamethasone 
at 0.1，1.0 and 3.0 mg/kg and the respective paired groups of animals that received 
provocative motion. Motion had no action to modify serum ACTH levels (P>0.05; 
Figure 3.20D). Similarly, betamethasone treatment failed to modify cortisol or 
ACTH levels in the stationary control animals (P>0.05; Figure 3.20C and Figure 
3.20D). 
3.2.3.3 Effect of methylprednisolone 
In the experiments involving the use of methylprednisolone, only 7 out of 9 control 
animals exhibited episodes of retching and/or vomiting (latency in responding 
animals was 3.1±0.4 min; see Figure 3.21A). Methylprednisolone (0.3-30 mg/kg) 
failed to modify significantly (P>0.05) the numbers of emetic episodes induced by 
provocative motion (control episodes were 2.8±0.9, Figure 3.21B) and also failed to 
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modify significantly the cortisol CP>0.05; Figure 3.21C) or ACTH (P>0.05; Figure 
3.21D) levels in stationary control animals. 
However, provocative motion induced a 270.5 % increase in cortisol levels of 
vehicle treated group (stationary controls 3.4t0.9 ^ig/dl, provocative motion 
challenged 12.4±2.9 ^ig/dl，P<0.05) that was antagonised significantly by 
methylprednisolone at 3 and 10 mg/kg (P<0.05; Figure 3.21C). The higher dose of 
30 mg/kg failed to reduce cortisol levels (P>0.05). Motion did not significantly 
affect ACTH levels {P>0.05; Figure 3.21D). 
it 
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3.2.4 The Effect ofDexamethasone on Motion-Induced Emesis and Cortisol and 
ACTHLevels in Motion-Sensitive Suncus murinus 
、 
Dexamethasone was the only glucocorticoid capable .of antagonising emesis in the 
initial motion-induced emesis experiments conducted during the course ofthis thesis. 
The anti-emetic action was apparent only in female animals and motion did not 
induce a corresponding increase in cortisol levels in the experiments. 
A new group of motion-sensitive animals were therefore selected to re-test the anti-
emetic potential of dexamethasone following protocol developed by Torii and co-
workers (1991b). The protocol involves a screening process to identify motion 
sensitive animals prior to the administration of drugs. Only animal exhibiting > 2 
episodes of retching and/or vomiting to provocative motion were used in the drug 
studies. 
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3.2.4.1 Effect of dexamethasone on male motion-sensitive animals 
On the test day, motion induced 5.0i l .2 episodes of retching and/or vomiting. The 
latency to onset of emesis was 2.5i0.4 min. However, dexamethasone 0.01-1.0 
mg/kg failed to modify the number of episodes of retching and/or vomiting (P>0.05; 
Figure 3.22B) or the latency to onset of emesis induced by the provocative motion 
stimulus (P>0.05; Figure 3.22A). 
Compared to the stationary control motion sensitive animals, the motion-induced 
cortisol elevation on the drug test was antagonised significantly by dexamethasone 
0.01-1 mg/kg (P<0.05; Figure 3.22C). However, the antagonism appeared 'U'-
shaped in that the higher dose of 1 mg/kg was less effective to antagonise the 
motion-induced increase. No obvious dose-related pattern of activity was seen with � 
dexamethasone on ACTH levels (P>0.05) although -there were some significant 
differences between the parallel group of animals receiving dexamethasone at 0.3 
mg/kg (P<0.05; see Figure 3.22D). 
3.2.4.2 Effect ofdexamethasone on female motion-sensitive animals 
On the test day, motion induced 5.2±1.0 episodes of retching and/or vomiting. The 
latency to onset of retching and/or vomiting was 2.2i0.5 min. The animals acted as 
their own control and dexamethasone failed to affect either the latency to onset 
(P>0.05; Figure 3.23A) or the total number of episodes of retching and/or vomiting 
induced by motion (P>0.05; Figure 3.23B). However, there was an apparent delay in 
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motion-induced emesis in animals treated with dexamethasone 0.01 mg/kg (P<0.05; 
Figure 3.23A) from data collected on the test day. 
The cortisol and ACTH levels in the motion-tested animals were compared to the 
levels of motion sensitive animals that acted as stationary controls. There was no 
evidence that motion induced increases in cortisol or ACTH levels in the vehicle 
treated animals (P>0.05). Further, there was no evidence that dexamethasone could 
dose-dependently modify cortisol or ACTH levels (P>0.05) but there were 
significant differences in hormone levels between some of the groups that received 
1» 
dexamethasone and motion (P<0.05^see Figure 3.23C and Figure 3.23D). 
、 
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Figure 3.1 General profile of retching + vomiting induced by a single injection of 
cisplatin (5 mg/kg, i.p.) in (A) the castrated male ferret or (B) the normal female 
ferret. Cisplatin was injected at t = 0 h followed 30 sec later by distilled water. 
Distilled water administration was repeated every 8 h for the duration of the 
experiment. Results represent the means±s.e.mean of the total numbers of the 
retches + vomits occurring in 1 h time intervals (pooled control data from the 
experiments utilising distilled water as the vehicle; 9 male, 9 female). Distilled water 
administration is indicated as filled circles. 
I* 
ff 
A :5 40n 




+ |h|, ,T T .A 
1 oi 4_,4 ^^ . T l4h_l__W4 
^ 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 
- 仏 • • • • • • • • • 
B - 40n w T 
• i"M 
I 
> 20 - 1 1 Ijl] j | 
1 0 1 , ^ hijii rt … , ^ J | I i t i _ | i u _ _ i i _ h\ 4 
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 
• • 參 參 鲁 • • • 參 
Time (h) . 
. 99 
Figure 3.2 The effect of (A) vehicle (distilled water) 0.5 ml/kg, (B) 
dexamethasone 0.1 mg/kg, (C) dexamethasone 0.3 mg/kg or (D) dexamethasone 1.0 
mg/kg on the profile of retching + vomiting in the ferret induced by a single injection 
of cisplatin, 5 mg/kg. All drugs were administered intraperitoneally. Cisplatin was 
injected at t = 0 h followed 30 sec later by dexamethasone or vehicle administration. 
Dexamethasone or vehicle administration was repeated every 8 h for the duration of 
the experiment. Results represent the meansis.e.mean of the total numbers of the 
retches + vomits occurring in 1 h time intervals (n=6). Dexamethasone or vehicle 





















































































































































































































































































































































































Figure 3.3 The effect of (A) vehicle (distilled water) 0.5 ml/kg, (B) betamethasone 
0.3 mg/kg, (C) betamethasone 1.0 mg/kg or (D) betamethasone 3.0 mg/kg on the 
profile of retching + vomiting in the ferret induced by a single injection of cisplatin, 5 
mg/kg. All drugs were administered intraperitoneally. Cisplatin was injected at t = 0 
h followed 30 sec later by betamethasone or vehicle administration. Betamethasone 
or vehicle administration was repeated every 8 h for the duration of the experiment. 
Results represent the means±s.e.mean of the total numbers of the retches + vomits 
occurring in 1 h time intervals (n=4). Betamethasone or vehicle administration is 




































































































































































































































































































































































































































































































































Figure3.4 The effect of (A) vehicle (distilled water) 1.0 ml/kg, (B) 
methylprednisolone 1.0 mg/kg, (C) methylprednisolone 3.0 mg/kg or (D) 
methylprednisolone 10.0 mg/kg on the profile of retching + vomiting in the ferret 
induced by a single injection of cisplatin, 5 mg/kg. All drugs were administered 
intraperitoneally. Cisplatin was injected at t = 0 h followed 30 sec later by 
methylprednisolone or vehicle administration. Methylprednisolone or vehicle 
administration was repeated every 8 h for the duration of the experiment. Results 
represent the means±s.e.mean of the total numbers of the retches + vomits occurring 
in 1 h time intervals (n=4). Methylprednisolone or vehicle administration is indicated 











































































































































































































































































































































































Figure 3.5 The effect of (A) vehicle (distilled water) 0.5 ml/kg, (B) hydrocortisone 
1.0 mg/kg, (C) hydrocortisone 3.0 mg/kg, (D) hydrocortisone 10.0 mg/kg or (E) 
hydrocortisone 30.0 mg/kg on the profile of retching + vomiting in the ferret induced 
by a single injection of cisplatin, 5 mg/kg. All drugs were administered 
intraperitoneally. Cisplatin was injected at t = 0 h followed 30 sec later by 
hydrocortisone or vehicle administration. Hydrocortisone or vehicle administration 
was repeated every 8 h for the duration of the experiment. Results represent the 
means±s.e.mean of the total numbers of the retches + vomits occurring in 1 h time 



























































































































































































































































































































































































































































































































Figure3.6 The effect of (A) vehicle (45% molecusol) 1.0 ml/kg, (B) 
fludrocortisone 1.0 mg/kg, (C) fludrocortisone 3.0 mg/kg or (D) fludrocortisone 10.0 
mg/kg on the profile of retching + vomiting in the ferret induced by a single injection 
of cisplatin, 5 mg/kg. All drugs were administered intraperitoneally. Cisplatin was 
injected at t = 0 h followed 30 sec later by fludrocortisone or vehicle administration. 
Fludrocortisone or vehicle administration was repeated every 8 h for the duration of 
the experiment. Results represent the means±s.e.mean of the total numbers of the 
retches + vomits occurring in 1 h time intervals (n=4). Fludrocortisone or vehicle 












































































































































































































































































































































































Figure3.7 The effect of dexamethasone (Dex), betamethasone (Beta), 
methylprednisolone (Methylpred), hydrocortisone (Hydro) or fludrocortisone (Fludro) 
or their respective vehicles, on the profile of retching + vomiting in the ferret induced 
by a single injection of cisplatin, 5 mg/kg. All drugs were administered 
intraperitoneally. Cisplatin was injected at t = 0 h followed 30 sec later by 
corticosteroid or vehicle administration. Corticosteroid or vehicle administration was 
repeated every 8 h for the duration of the experiment. Results represent the 
meanis.e.mean o f t h e total numbers of retches + vomits occurring in 0-24, 24-56 and 
56-72 h time intervals (n=4-6). Significant differences in retching + vomiting in 
cisplatin vehicle treated animals and the respective cisplatin corticosteroid treated 
animals are indicated as ><0.05，*><0.01 or " > < 0 . 0 0 5 (one way ANOVA followed 
by Fisher's PLSD tests). 
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Figure3.8 The effect of dexamethasone, betamethasone, methylprednisolone, 
hydrocortisone or fludrocortisone or their respective vehicles on the latency to onset 
ofretching + vomiting in the ferret induced by a single injection ofcisplatin, 5 mg/kg. 
All drugs were administered intraperitoneally. Cisplatin was injected at t = 0 h 
followed 30 sec later by corticosteroid or vehicle administration. Corticosteroid or 
vehicle administration was repeated every 8 h for the duration of the experiment. 
Results represent the mean of data only from the animals that developed a retching 
and/or vomiting response. The numbers of animals exhibiting retching and/or 
vomiting out of the number of animals tested is indicated as a ‘fraction, for each 
treatment group. Significant difference on the latency to onset ofretching + vomiting 
in cisplatin corticosteroid treated animals are indicated as *P<0.05 (one way ANOVA 
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Figure 3.9 The effect of (A) vehicle (distilled water) or (B) dexamethasone 1.0 
mg/kg on the profile of retching + vomiting in the ferret induced by a single injection 
of cisplatin, 5 mg/kg. All drugs were administered intraperitoneally. Cisplatin was 
injected at t = 0 h followed 24 h later by dexamethasone or vehicle administration. 
Dexamethasone or vehicle administration was repeated every 8 h for the duration of 
the experiment. Results represent the mean±s.e.mean of the total numbers of retches 
+ vomits occurring in 1 h time intervals (n=4). Dexamethasone or vehicle 











































































































































































































































































































Figure 3.10.0 The effect of (A) vehicle (0.96% benzyl alcohol in saline) 0.1 ml/kg, 
i.m., or (B) cortrosyn depot 0.1 mg/kg, i.m., on the profile of retching + vomiting in 
the ferret induced by a single injection of cisplatin, 5 mg/kg, i.p.. Cortrosyn depot or 
vehicle was administered 4 h prior to the injection of cisplatin, which was 
administered at t = 0 h. Cortrosyn depot or vehicle administration was repeated at t = 
8 h, and then at every 12 h for the duration of the experiment. Results represent the 
means±s.e.mean of the total numbers of the retches + vomits occurring in 1 h time 







































































































































































































































































Figure 3.10.1 The effect of cortrosyn depot or vehicle on the latency to onset of 
retching + vomiting and on the profile of retching + vomiting in the ferret induced by 
a single injection of cisplatin, 5 mg/kg. In the latency graph, results represent the 
mean of data only from the animals that developed a retching and/or vomiting 
response. The numbers of animals exhibiting retching and/or vomiting out of the 
number ofanimals tested is indicated as a ‘fraction，for each treatment group. Results 
also represent the meanis.e.mean of the total numbers of retches + vomits occurring 
in 0-24, 24-48, 48-72, 24-56 and 56-72 h time intervals. Significant differences in 
cisplatin cortrosyn treated animals and cisplatin vehicle treated animals are indicated 
as ><0.05 (one way ANOVA followed by Fisher's PLSD tests). 
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Figure 3.11.0 The effect of (A) vehicle (saline) 0.5 ml/kg, (B) metyrapone 10 mg/kg 
or (C) metyrapone 30 mg/kg on the profile of retching + vomiting in the ferret induced 
by a single injection of cisplatin, 5 mg/kg. All drugs were administered 
intraperitoneally. Metyrapone or vehicle was administered 4 h prior to the injection of 
cisplatin, which was injected at t = 0 h. Metyrapone or vehicle administration was 
repeated at 30 sec, and then at every 8 h for the duration o f the experiment. Results 
represent the means±s.e.mean of the total numbers of the retches + vomits occurring 













































































































































































































































































































































































Figure 3.11.1 The effect of metyrapone or vehicle on the latency to onset of retching 
+ vomiting and on the profile of retching + vomiting in the ferret induced by a single 
injection of cisplatin, 5 mg/kg. In the latency graph, results represent the mean of data 
only from the animals that developed a retching and/or vomiting response. The 
numbers of animals exhibiting retching and/or vomiting out of the number of animals 
tested is indicated as a ‘fraction，for each treatment group. Results also represent the 
mean±s.e.mean of the total numbers of retches + vomits occurring in 0-24, 24-48, 48-
72, 24-56 and 56-72 h time intervals. Significant differences in cisplatin metyrapone 
treated animals and cisplatin vehicle treated animals are indicated as *P<0.05 (one 
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Figure 3.12.0 The effect of (A) vehicle (10 % NaHCO3) 2.0 ml/kg, (B) indomethacin 
3.0 mg/kg, (C) indomethacin 10.0 mg/kg or (D) indomethacin 30.0 mg/kg on the 
profile of retching + vomiting in the ferret induced by a single injection of cisplatin, 5 
mg/kg. All drugs were administered intraperitoneally. Cisplatin was injected at t = 0 
h followed 30 sec later by indomethacin or vehicle administration. Indomethacin or 
vehicle administration was repeated every 8 h for the duration of the experiment. 
Results represent the means±s.e.mean of the total numbers of the retches + vomits 
occurring in 1 h time intervals (n=4-5). Indomethacin or vehicle administration is 



































































































































































































































































































































































































































































































































































































Figure 3.12.1 The effect of indomethacin or vehicle on the latency to onset of 
retching + vomiting and on the profile of retching + vomiting in the ferret induced by 
a single injection of cisplatin, 5 mg/kg. In the latency graph, results represent the 
mean of data only from the animals that developed a retching and/or vomiting 
response. The numbers of animals exhibiting retching and/or vomiting out of the 
number ofanimals tested is indicated as a ‘fraction’ for each treatment group. Results 
also represent the mean±s.e.mean of the total numbers of retches + vomits occurring 
in 0-24，24-48, 48-72, 24-56 and 56-72 h time intervals. Significant differences in 
cisplatin indomethacin treated animals and cisplatin vehicle treated animals are 
indicated as ><0 .05 (one way ANOVA followed by Fisher's PLSD tests). 
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Figure3.12.2 The effect of (A) vehicle (60% PEG200) 2.0 ml/kg, (B) DFU 1.0 
mg/kg, (C) DFU 3.0 mg/kg or (D) DFU 10.0 mg/kg on the profile of retching + 
vomiting in the ferret induced by a single injection of cisplatin, 5 mg/kg. All drugs 
were administered intraperitoneally. Cisplatin was injected at t = 0 h. Results 
represent the means±s.e.mean of the total numbers of the retches + vomits occurring 






















































































































































































































































































































































































































Figure 3.12.3 The effect of DFU or vehicle on the latency to onset of retching + 
vomiting and on the profile of retching + vomiting in the ferret induced by a single 
injection ofcisplatin, 5 mg/kg. In the latency graph, results represent the mean ofdata 
only from the animals that developed a retching and/or vomiting response. The 
numbers ofanimals exhibiting retching and/or vomiting out of the number of animals 
tested is indicated as a ‘fraction’ for each treatment group. Results also represent the 
meanis.e.mean of the total numbers of retches + vomits occurring in 0-40，40-48, 48-
56 and 56-72 h time intervals. Significant differences in cisplatin DFU treated animals 
and cisplatin vehicle treated animals are indicated as *P<0.05 (one way ANOVA 
















































































































































































































































































Figure 3.12.4 The effect of (A) vehicle (25% molecusol) 1.0 ml/kg or (B) L-745,337 
10 mg/kg on the profile of retching + vomiting in the ferret induced by a single 
injection of cisplatin, 5 mg/kg. All drugs were administered intraperitoneally. 
Cisplatin was injected at t = 0 h. Results represent the means±s.e.mean of the total 
numbers of the retches + vomits occurring in 1 h time intervals (n=4). L-745,337 or 









































































































































































































































































Figure 3.12.5 The effect ofL-745,337 or vehicle on the latency to onset ofretching + 
vomiting and on the profile of retching + vomiting in the ferret induced by a single 
injection of cisplatin, 5 mg/kg. In the latency graph, results represent the mean ofdata 
only from the animals that developed a retching and/or vomiting response. The 
numbers of animals exhibiting retching and/or vomiting out of the number of animals 
tested is indicated as a ‘fraction，for each treatment group. Results also represent the 
meanis.e.mean of the total numbers of retches + vomits occurring in 0-40, 40-48，48-
56 and 56-72 h time intervals. These were no significant differences in cisplatin L-
745,337 treated animals and cisplatin vehicle treated animals (P>0.05; one way 
ANOVA followed by Fisher's PLSD tests). 
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Figure 3.13.0 The effect of (A) vehicle (25 % molecusol) 2.0 ml/kg, (B) MK-886 1.0 
mg/kg, (C) MK-886 3.0 mg/kg or (D) MK-886 10.0 mg/kg on the profile ofretching + 
vomiting in the ferret induced by a single injection of cisplatin, 5 mg/kg. All drugs 
were administered intraperitoneally. Cisplatin was injected at t = 0 h followed 30 sec 
later by MK-886 or vehicle administration. MK-886 or vehicle administration was 
repeated every 8 h for the duration of the experiment. Results represent the 
means±s.e.mean of the total numbers of the retches + vomits occurring in 1 h time 
























































































































































































































































































































































































Figure 3.13.1 The effect o fMK-886 or vehicle on the latency to onset of retching + 
vomiting and on the profile of retching + vomiting in the ferret induced by a single 
injection ofcisplatin, 5 mg/kg. In the latency graph, results represent the mean ofdata 
only from the animals that developed a retching and/or vomiting response. The 
numbers of animals exhibiting retching and/or vomiting out o f the number of animals 
tested is indicated as a ‘fraction，for each treatment group. Results also represent the 
meanis.e.mean of the total numbers of retches + vomits occurring in 0-24, 24-48, 48-
72，24-56 and 56-72 h time intervals. There were no significant differences in 
cisplatin MK-886 treated animals and cisplatin vehicle treated animals (P>0.05; one 
way ANOVA followed by Fisher's PLSD tests). 
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Figure 3.14.0 The effect of (A) vehicle + vehicle (10% NaHCO3; 1 ml/kg and 25 % 
molecusol; 2 ml/kg), (B) indomethacin 10 mg/kg + 25 % molecusol, (C) MK-886 10 
mg/kg + 10% NaHCO3, (D) indomethacin 10 mg/kg + MK-886 10 mg/kg or (E) 
dexamethasone 1.0 mg/kg on the profile of retching + vomiting in the ferret induced 
by a single injection of cisplatin, 5 mg/kg. All drugs were administered 
intraperitoneally. Cisplatin was injected at t = 0 h followed 30 sec later by 
indomethacin or vehicle and/or MK-886 or vehicle administration. Indomethacin or 
vehide and/or MK-886 or vehicle administration was repeated every 8 h for the 
duration of the experiment. Results represent the meansis.e.mean of the total 
numbers of the retches + vomits occurring in 1 h time intervals (n=3-4). Indomethacin 
or vehicle and/or MK-886 or vehicle, and dexamethasone or vehicle administration is 






















































































































































































































































































































































































































































































































































































































Figure 3.14.1 The effect of indomethacin (Indo) or vehicle, NaHCO3 (Vehl) and/or 
MK-886 (MK) or vehicle, 25% molecusol (Veh 2) on the latency to onset of retching 
+ vomiting and on the profile of retching + vomiting in the ferret induced by a single 
injection ofcisplatin, 5 mg/kg. In the latency graph, results represent the mean ofdata 
only from the animals that developed a retching and/or vomiting response. The 
numbers of animals exhibiting retching and/or vomiting out of the number of animals 
tested is indicated as a ‘fraction，for each treatment group. Results also represent the 
meanis.e.mean of the total numbers of retches + vomits occurring in 0-24, 24-48, 48-
72, 24-56 and 56-72 h time intervals. Data is compared with dexamethasone 1 mg/kg 
(Dex). Significant differences in cisplatin drug treated animals and cisplatin vehicle 
















^ VJ  + 
w  s 




 4/4  3/4  ^  250
-




 -  H  • ot_U—
U—












































 MK  MK  Ve
hl 
















1  *  300
-






馳  r^  ^  i.  H  r-
^ 
1  i.  nM
^
 ^  p^  H  , 




















































 MK  MK  Ve
hl 










.¾ +  .
把




 ^  y  n^  i 
^  r^  ^  -00
.
 f^  f^  nuM
^ 
^, 3  】 
















































 MK  MK  Ve
hl 







Figure 3.15 Scatter plot of correlation between serum ACTH and (A) latency; (B) 
episodes, (C) retches and (D) vomits in male and female Suncus murinus. The straight 
line represents the best-fit-line of the mean and 'r ' is the correlation coefficient (range 
is 0 to 1, where 0 stands for no correlation). Significant differences of r values 
relative to 0 is indicated as P<0.05. 95 % confidence intervals for the mean are also 
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Figure3.16 The effect of dexamethasone on motion-induced emesis and serum 
cortisol and ACTH levels in motion naive male Suncus murinus. Dexamethasone or 
vehicle was administered as a 60 min pretreatment prior to randomising the animals 
into 2 groups. One group of animals was placed into observation chambers and 
received 5 min ofmotion (Provocative Motion; 4 cm horizontal displacement at 1 Hz). 
The other group of animals acted as control animals that were placed in the 
observation chambers for 5 min under stationary conditions (Stationary Controls). The 
number of animals exhibited retching and/or vomiting out of the number of animals 
tested is indicated as a ‘fraction，for each treatment group. At the end of the 5 min 
period，the animals were decapitated to obtain blood for the analysis of cortisol and 
ACTH. Data represent the meanis.e.mean. of 7 determinations. There were no 
significant differences between the parameters of the different treatment groups 
(P>0.05; One-way ANOVA followed by Fishers' PLSD tests for the emesis data, 
analysis ofdata ofprovocative motion treated animals; 2 factor ANOVA followed by 
pre-planned contrasts of specified means for the neurochemical data). 
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Figure 3.17 The effect of betamethasone on motion-induced emesis and serum 
cortisol and ACTH levels in motion naive male Suncus murinus. Betamethasone or 
vehicle was administered as a 60 min pretreatment prior to randomising the animals 
into 2 groups. One group of animals was placed into observation chambers and 
received 5 min of motion (Provocative Motion; 4 cm horizontal displacement at 1 Hz). 
The other group of animals acted as control animals that were placed in the 
observation chambers for 5 min under stationary conditions (Stationary Controls). The 
number of animals exhibited retching and/or vomiting out of the number of animals 
II 
tested is indicated as a ‘fraction, for each treatment group. At the end of the 5 min 
period the animals were decapitated to obtain blood for the analysis of cortisol and 
ACTH. Data represent the meanis.e.mean of 7 determinations. For the emesis data, 
there were no significant differences between the treatment groups (analysis ofdata of 
provocative motion treated animals: P>0.05; One-way ANOVA followed by Fishers' 
PLSD tests). For the neurochemical data, significant differences between the 
treatment groups are indicated as *P<0.05 or **P<0.01 (2 factor ANOVA followed by 
pre-planned contrasts of specified means). 
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Figure 3 • 18 The effect of methylprednisolone on motion-induced emesis and serum 
cortisol and ACTH levels in motion naive male Suncus murinus. Methylprednisolone 
or vehicle was administered as a 60 min pretreatment prior to randomising the animals 
into 2 groups. One group of animals was placed into observation chambers and 
received 5 min of motion (Provocative Motion; 4 cm horizontal displacement at 1 Hz). 
The other group of animals acted as control animals that were placed in the 
observation chambers for 5 min under stationary conditions (Stationary Controls). The 
number of animals exhibited retching and/or vomiting out of the number of animals 
tested is indicated as a ‘fraction，for each treatment group. At the end of the 5 min 
period the animals were decapitated to obtain blood for the analysis of cortisol and 
ACTH. Data represent the mean±s.e.mean. of 7 determinations. For the emesis data, 
there were no significant differences between the treatment groups (analysis ofdata of 
provocative motion treated animals: P>0.05; One-way ANOVA followed by Fishers' 
PLSD tests). For the neurochemical data, significant differences between the 
treatment groups are indicated as *P<0.05 or **P<0.01 (2 factor ANOVA followed by 
pre-planned contrasts of specified means). 
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Figure 3.19 The effect of dexamethasone on motion-induced emesis and serum 
cortisol and ACTH levels in motion naive female Suncus murinus. Dexamethasone or 
vehicle was administered as a 60 min pretreatment prior to randomising the animals 
into 2 groups. One group of animals was placed into observation chambers and 
received 5 min of motion (Provocative Motion; 4 cm horizontal displacement at 1 Hz). 
The other group of animals acted as control animals that were placed in the 
observation chambers for 5 min under stationary conditions (Stationary Controls). 
The number of animals exhibited retching and/or vomiting out of the number of 
animals tested is indicated as a ‘fraction，for each treatment group. At the end of the 5 
min period the animals were decapitated to obtain blood for the analysis of cortisol 
and ACTH. Data represent the mean±s.e.mean of 12 determinations. Significant 
differences between the treatment groups are indicated as *P<0.05 (One-way 
ANOVA followed by Fishers' PLSD tests for the emesis data, analysis of data of 
provocative motion treated animals; 2 factor ANOVA followed by pre-planned 
contrasts of specified means for the neurochemical data). 
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Figure 3.20 The effect of betamethasone on motion-induced emesis and serum 
cortisol and ACTH levels in motion naive female Suncus murinus. Betamethasone or 
vehide was administered as a 60 min pretreatment prior to randomising the animals 
into 2 groups. One group of animals was placed into observation chambers and 
received 5 min of motion (Provocative Motion; 4 cm horizontal displacement at 1 Hz). 
The other group of animals acted as control animals that were placed in the 
observation chambers for 5 min under stationary conditions (Stationary Controls). The 
number of animals exhibited retching and/or vomiting out of the number of animals 
tested is indicated as a 'fraction' for each treatment group. At the end of the 5 min 
period the animals were decapitated to obtain blood for the analysis of cortisol and 
A C m Data represent the mean±s.e.mean of 9 determinations. For the emesis data, 
there were no significant differences between the treatment groups (analysis ofdata of 
provocative motion treated animals: P>0.05; One-way ANOVA followed by Fishers' 
PLSD tests). For the neurochemical data, significant differences between the 
treatment groups are indicated as *P<0.05 or **P<0.01 (2 factor ANOVA followed by 
pre-planned contrasts of specified means). 
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Figure 3.21 The effect of methylprednisolone on motion-induced emesis and serum 
cortisol and ACTH levels in motion naive female Suncus murinus. 
Methylprednisolone or vehicle was administered as a 60 min pretreatment prior to 
randomising the animals into 2 groups. One group of animals was placed into 
observation chambers and received 5 min of motion (Provocative Motion; 4 cm 
horizontal displacement at 1 Hz). The other group ofanimals acted as control animals 
that were placed in the observation chambers for 5 min under stationary conditions 
(Stationary Controls). The number of animals exhibited retching and/or vomiting out 
of the number of animals tested is indicated as a ‘fraction, for each treatment group. 
At the end of the 5 min period the animals were decapitated to obtain blood for the 
analysis ofcortisol and ACTH. Data represent the mean±s.e.mean o f 9 determinations. 
For the emesis data, there were no significant differences between the treatment 
groups (analysis of data of provocative motion treated animals: P>0.05; One-way 
ANOVA followed by Fishers' PLSD tests). For the neurochemical data, significant 
differences between the treatment groups are indicated as *P<0.05 or **P<0.01 (2 
factor ANOVA followed by pre-planned contrasts ofspecified means) 
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Figure 3.22 The effect of dexamethasone on motion-induced emesis and serum 
cortisol and ACTH levels in motion sensitive male Suncus murinus. Animals were 
initially tested to determine their sensitivity to motion (Initial Test; 4 cm horizontal 
displacement at 1 Hz for 5 min). Animals that failed to exhibit > 2 episodes of 
retching and/or vomiting were excluded from further experimentation. 14 days after 
the screening procedure the motion-sensitive animals that had > 2 episodes were 
pretreated for 60 min with dexamethasone or vehicle and re-exposed to motion (Drug 
Test; 4 cm horizontal displacement at 1 Hz for 5 min). The number of animals 
exhibited retching and/or vomiting out of the number ofanimals tested is indicated as 
a ‘fraction, for the motion sensitive animals. At the end of the 5 min period, the 
animals were decapitated to obtain blood for the analysis of cortisol and ACTH. 
Control sets of animals were decapitated for comparative purposes of cortisol and 
ACTH levels. The control animals were a population of Suncus murinus that exhibited 
- 2 emetic episodes following an initial motion ( 4 cm horizontal displacement at 1 Hz 
for 5 min) challenge. The control animals received a 60 min pretreatment of 
dexamethasone or vehicle before being placed into observation chambers for 5 min 
under stationary conditions (Stationary Controls). Data represent the mean±s.e.mean 
of 7 determinations. For the emesis data, there was no significant difference between 
the treatment groups (P>0.05; repeated measures two factor ANOVA followed by pre-
planned contrasts of specified means). For the neurochemical data, the significant 
difference between the treatment groups is indicated as *P<0.05 or **P<0.01 (2 factor 
ANOVA followed by pre-planned contrasts ofspecified means). 
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Figure 3.23 The effect of dexamethasone on motion-induced emesis and serum 
cortisol and ACTH levels in motion sensitive female Suncus murinus. Animals were 
initially tested to determine their sensitivity to motion (Initial Test; 4 cm horizontal 
displacement at 1 Hz for 5 min). Animals that failed to exhibit > 2 episodes of 
retching and/or vomiting were excluded from further experimentation. 14 days after 
the screening procedure the motion-sensitive animals that had > 2 episodes were 
pretreated for 60 min with dexamethasone or vehicle and re-exposed to motion (Drug 
Test; 4 cm horizontal displacement at 1 Hz for 5 min). The number of animals 
exhibited retching and/or vomiting out of the number of animals tested is indicated as 
a ‘fraction’ for the motion sensitive animals. At the end of the 5 min period the 
animals were decapitated to obtain blood for the analysis of cortisol and ACTH. 
Control sets of animals were decapitated for comparative purposes of cortisol and 
ACTH levels. The control animals were a population of Suncus murinus that exhibited 
^ 2 emetic episodes following an initial motion ( 4 cm horizontal displacement at 1 Hz 
for 5 min) challenge. The control animals received a 60 min pretreatment of 
dexamethasone or vehicle before being placed into observation chambers for 5 min 
under stationary conditions (Stationary Controls). Data represent the meanis.e.mean 
of 9 determinations. For the emesis data, the significant difference between the 
treatment groups is indicated as *P<0.05 or **P<0.01 (repeated measures two factor 
ANOVA followed by pre-planned contrasts of specified means). For the 
neurochemical data, the significant difference between the treatment groups is 
indicated as *P<0.05 (2 factor ANOVA followed by pre-planned contrasts of 
specified means). 
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4.1 Cisplatin (5 mg/kg, i.p.)-Induced Emesis in Control Animals 
Cisplatin at 5 mg/kg, i.p. induced two distinct phases of retching and vomiting in the 
ferret. There was an initial acute phase that started at 5.6±1.4 h following cisplatin 
administration (data pooled from cisplatin vehicle treated control animals that 
exhibited acute emesis, n=13) and intensity of emesis started to decrease at 16 h. 
The initial emetic response was followed by a period where emesis was less frequent. 
In the latter delayed phase, starting at 24 h, the animals experienced retching and 
ff 
vomiting response with intensity returning to maximum at approximately 32 h. The 
pattern of emesis induced by cisplatin 5 mg/kg was similar to that previously 
reported (Rudd et cd., 1996a; Rudd & Naylor，1996; Tattersall et al, 2000). 
、 
In the present studies, the sensitivity of the ferret to the acute emetic action of 
cisplatin (5 mg/kg) was variable. Most ferrets developed emesis after a latency of 
approximately 8 h but some animals did not develop emesis until approximately 40 
h. The dose of cisplatin at 5 mg/kg may be a threshold dose to induce emesis (Rudd 
et cd., 1996b). The data from the present studies did not show an obvious sex 
difference in the sensitivity of cisplatin-induced emesis. However, the experiments 
utilised castrated male animals and therefore the situation may be different from 
normal animals, where the testosterone level is higher. In the clinic, female patients 
suffer more frequently and experience more severe nausea and vomiting than male 
patients treated with chemotherapy (Matsuki et al., 1997). 
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4.2 Anti-Emetic Action of Corticosteroids in the Ferret 
The present studies used dexamethasone as the reference corticosteroid. The drug 
was utilised at doses that are 3-15 higher than anti-emetic doses used in the clinic 
(Lacy et al., 1997-98). The doses used are also considered slightly higher than the 
recommended doses to reduce inflammation (i.e. 0.01-0.1 mg/kg; (Lacy et al., 1997-
98)). 
1» 
Initially，the studies were designed to assess the anti-emetic activity of 
corticosteroids on a day-by-day basis. However, at the end of the studies, it was 
apparent that the corticosteroids were particularly effective to antagonise emesis 
during the 24-56 h period. It therefore seemed more appropriate to consider the data� 
as the initial 24 h phase and the 24-56 h 'corticosteroid sensitive' phase, and the later 
56-72 h glucocorticoid insensitive phase. A discussion of the findings will be made 
after first comparing the data with previous findings in the ferret. 
The present studies have partially confirmed the anti-emetic action ofdexamethasone 
administered three times per day to reduce significantly the retching and vomiting 
response induced by a single administration of cisplatin (Rudd & Naylor, 1996). 
However, in the present studies, betamethasone appeared to be the superior anti-
emetic drug. Dexamethasone (1 mg/kg, i.p.) antagonised the total number ofretches 
+ vomits on day 1, 2 and 3 by 60，97 and 6 % respectively. Surprisingly, 
dexamethasone at 1 mg/kg was not effective in reducing emesis on day 3. The 
original data produced by Rudd & Naylor (1996) revealed that dexamethasone 
reduced the retching and vomiting response on day 1, 2 and 3 respectively by 85, 97 
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and 86 %. It is not known if the discrepancy is related to genetic factors (the animals 
in this study were from Australia and New Zealand, and the animals in the Rudd & 
Naylor study were from United Kingdom), or because the animals used in this study 
were castrated compared to the normal animals in the other study. 
Based on the anti-emetic activity of dexamethasone (present studies, Fukunaka et al., 
1998; Rudd & Naylor, 1996; Tattersall et al., 2000) and betamethasone, an 
inflammatory response and/or involvement of inflammatory mediators/products may 
i> 
contribute to the initial phase (0-24 h) of emesis induced by cisplatin. Unfortunately, 
ff 
a stronger argument cannot be made from the experiments involving 
methylprednisolone and hydrocortisone since some of the animals in the control 
groups failed to develop a strong emetic response during this period. Betamethasone 
clearly dose-dependently antagonised the early emetic response by up to 99.5% with 
dexamethasone producing a non-significant trend for a 25.7-64.0 % reduction. In the 
clinic, dexamethasone can produce comparable reductions in acute emesis, when 
used against less emetogenic chemotherapeutic agents (Fauser et al, 1999). 
However, there have been no dose-ranging studies or dose-response relationships 
reported for different corticosteroids to antagonise delayed emesis (Cersosimo & 
Karp，1986). It is therefore unknown ifhigher doses ofcorticosteroids in man would 
provide an improved inhibition of emesis without major side-effects (Fauser et al., 
1999). 
Glucocorticoids differ considerably in their estimated glucocorticoid and 
mineralocorticoid potencies and plasma half-lives (Dollery, 1991a; Rang et al, 
1995). The relatively potency of the anti-leukemic activity of dexamethasone and 
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prednisolone is 5.5 to 1 (Ito et al., 1996). The value is similar to their relative anti-
inflammatory activity. Generally, 1 mg of dexamethasone has been considered to be 
equivalent to 5 to 10 mg of prednisolone (Ito et al., 1996). Further, 1 mg of 
dexamethasone is considered to be equivalent to same amount of betamethasone, 15 
mg fludrocortisone or 30 mg of hydrocortisone (Britain, March 2000a; Dollery, 
1991a). 
The rank order of anti-emetic activity of the glucocorticoids to reduce emesis in the 
24-56 h period is remarkably similar to their known rank"order of anti-inflammatory 
r 
potency where dexamethasone and betamethasone are approximately equipotent but 
more potent than methylprednisolone and hydrocortisone respectively (Blaurence & 
Bennett, 1987; Schimmer & Parker，1996). Whilst fludrocortisone has glucocorticoid 
% 
activity, it is approximately 125-300 times more potent than hydrocortisone as a 
mineralocorticoid; the other corticosteroids tested have negligible mineralocorticoid 
activity (Rang et aL’ 1995). Hydrocortisone may have been expected to be a more 
potent anti-emetic but the difference is likely due to the compounds additional 
mineralocorticoid activity and relatively short plasma half life (Begg et al., 1987). In 
comparison, dexamethasone was more active than fludrocortisone to support a role 
of glucocorticoid receptors in the emetic response. 
It is interesting, however, that the glucocorticoids were ineffective to reduce emesis 
occurring after the 56 h period. Only fludrocortisone showed a trend to reduce 
emesis during this period. The reduction may indicate that mineralocorticoid 
receptors are involved in the latter part of the emetic response. If this is the case, it 
could be hypothesised that fludrocortisone reduces emesis by reducing sodium loss 
135 
via the kidney. Further experiments using other mineralocorticoids are required to 
test the hypothesis. 
It has been suggested that delayed emesis is primarily mediated by neurotransmitters 
other than 5-HT (Kris et al., 1994). Dexamethasone is not active to prevent 
apomorphine, morphine or copper sulphate-induced emesis in the ferret to indicate 
that the anti-emetic action is not mediated by a generalised action on the emetic 
reflex where inflammation does not occur (Rudd et cd., 1996a). However, the rank 
order of potency studies with the glucocorticoids in the initial studies in this thesis 
产 
suggests that inflammation occurs in response to cisplatin administration. 
Prostaglandins are well known inflammatory mediators such as the involvement in 
% 
pain and swelling (Baxendale et al., 1993; Williams et al., 1999). There is evidence 
that prostanoids are associated with emesis (Baird et al., 1995). For example, 
ibuprofen and indomethacin can attenuate radiation-induced emesis (see 
introduction) and prostanoid turnover can be increased by doxorubicin in rats or by 
local radiation in guinea pig (Sanger, 1993). However, low-dose cisplatin 50 mg/m^ 
does not increase the plasma levels of prostaglandins, including PGF2a, 6-keto PGFia 
and PGE2, in cancer patients during the acute phase of emesis (Curry et al., 1981). 
Unfortunately, the studies need to be repeated against high-dose cisplatin where 
samples are taken directly during the delayed phase to re-examine a potential 
prostaglandin involvement. However, it has been suggested that only slightly 
elevated amounts of prostanoids are required to activate the emetic reflex (Rudd et 
al., 1996a) and activation of DP-, EP- and TP- prostanoid receptors can result in 
dose-related retching and vomiting (Rudd, personal communication). 
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Inflammation involves components of the immune response and many different 
mediators (Leirisalo-Repo, 1994; Levy, 1996), some of which are known to activate 
the emetic reflex. The classical mediators that are emetic include histamine 
(Bhargava & Dixit, 1968)，5-HT (see introduction), prostaglandins (see above), 
substance P (Gardner et al., 1994) and possibly leukotrienes (Jett et al., 1990). It is 
well known that glucocorticoids decrease histamine production and/or release from 
mast cells (Hirasawa et al., 1990) and prevent the synthesis of prostaglandins, 
thromboxanes and leukotrienes (Vane & Botting, 1996). Less information is 
available about the emetic potential of other inflammatory mediators such as nitric 
r 
oxide, bradykinin, cytokines and oxygen-derived free radicals, which are also 
involved in inflammation and regulated by glucocorticoids (Bames & Adcock, 1993; 
Dray & Bevan，1993; Moncada & Palmer，1991; Willemart et al., 1998). 
If inflammation is involved in the mechanism of delayed emesis, a critical question 
arising would be how can cisplatin activate the inflammatory response or elevate 
levels of inflammatory mediators? Perhaps the trigger for cisplatin to induce 
inflammation or the production of inflammatory mediators could relate to its 
cytotoxic and neurotoxic action (Scott et aL, 1994) or the ability to modulate 
cytokine levels (Coulon et al., 1993; Preziosi et al., 1992b; Rabinowitz et al., 1993). 
Recent studies suggest that interleukins, (IL; e.g. IL-ip, IL-6, IL-8), macrophage 
colony-stimulating factor or even tumour necrosis factor-a may be key players in the 
triggering the mechanism as they are elevated following cisplatin treatment 
(Pogrebniak et al., 1991; Rabinowitz et aL, 1993; Shi et al.’ 1998) and during 
‘sickness，behaviour (Kent et al., 1992). Cisplatin also indirectly activates the 
inflammatory mechanism by reducing the levels of the natural ‘decoy receptor’ for 
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IL-ip (Arenberg et al., 1995). The corticosteroids are well known to prevent the 
production of the cytokines (Barnes & Adcock, 1993) and this action would 
presumably prevent the involvement of many of the other mediators involved in 
inflammation and possibly emesis. 
It is possible to hypothesise that the involvement of cytokines and other pro-
inflammatory mediators may occur early in response to cisplatin treatment since the 
dexamethasone was more effective to antagonise emesis if administered on the first 
day. The data is consistent with the clinical experience where a poor control of acute 
r-
emesis results in a delayed phase that is more difficult to control (Hesketh, 1996). 
However, the mechanism(s) contributing the emesis occurring after 56 h is unknown. 
、 
4.3 Metyrapone Study _  
The studies in the ferret suggest that activation of glucocorticoid receptors can 
reduce cisplatin-induced emesis. In the normal situation, the body can produce 
cortisol, the endogenous activator of the glucocorticoid receptors. Certainly, there 
are reports that plasma cortisol levels are inversely related to the development of 
chemotherapy-induced nausea and vomiting (Fredrikson et al., 1992; Hursti et al., 
1993). Therefore, inhibiting cortisol synthesis would be expected to exacerbate 
retching and vomiting. 
The study used metyrapone to test the hypothesis. No emesis was seen with 
metyrapone during the pretreatment time in the ferret. Consistent with the above 
hypothesis, metyrapone was found to potentiate acute emesis. This may be related to 
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a reduction in cortisol synthesis, although levels were not measured. However, 
administration of metyrapone could also be reasonably expected to reduce the 
negative feedback action that would normally be elevated by endogenous cortisol. 
The mechanism to potentiate emesis could therefore occur through elevating ACTH 
(Altmeyer et aL, 1986) or corticotrophin-releasing factor levels (Cole et al, 2000) 
that would normally be suppressed by cortisol or cortisol mimetics, like 
dexamethasone (Avgerinos et al., 1994). It would be of importance to test the action 
ofcorticotrophin releasing hormone antagonists in cisplatin-induced emesis model. 
I* 
ff 
Surprisingly, however, metyrapone was not active to potentiate emesis occurring 
during the delayed phase. If anything, a slight reduction was observed. This is not 
consistent with the above hypothesis, particularly since the 24-56 h phase is sensitive 
% 
to corticosteroids. It is possible that the mechanism of glucocorticoids (and cortisol) 
to reduce delayed emesis occurs at a level upstream the 11 P-hydroxylase step. 
Conversely, it is also possible that cortisol does not provide a tonic inhibitory control 
ofdelayed emesis and therefore a reduction in the levels of cortisol fails to impact on 
the development of the emetic response. Experiments with other antagonists of 
cortisol function are required to further test the hypothesis. Nevertheless, the 
experiments provide evidence that the acute and delayed phases of cisplatin-induced 
emesis are pharmacologically distinct in the ferret. 
4.4 Cortrosyn Depot Study 
Agents that modulate glucocorticoid receptors can affect ACTH levels (see above). 
Normally, glucocorticoids would be expected to reduce ACTH levels (see 
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introduction). However, there are studies showing that ACTH administration leads 
to reduction of chemotherapy-induced nausea and vomiting in man (Battelli et aL, 
1984; Colbert et al, 1983). Passalacaqua et al (1992) demonstrated a 68% reduction 
of cisplatin-induced delayed emesis by ACTH (1 mg/kg). Unfortunately, the effect 
of ACTH on acute emesis was not assessed in the study since the patients received 
combination of dexamethasone and ondansetron/metoclopramide on the first day of 
treatment. A follow-up study revealed that the anti-emetic action of ACTH was 
dose-related and that the most effective block of delayed emesis was on days 2 and 3. 
Interestingly, ACTH administration has also been found to reduce pregnancy-
tf 
induced sickness (Ylikorkala et al., 1979). 
The present studies selected cortrosyn depot (ACTH 1-24) to investigate the 
involvement of ACTH receptors in cisplatin-induced acute and delayed emesis 
model. The dose of cortrosyn 0.1 mg/kg used in the present study is approximately 
10 times higher than that used in the clinic to test adrenal function (Dollery, 1991b). 
Administration of the depot (0.25-1 mg) can produce a peak of cortisol concentration 
in approximately 8 h with elevation lasting for up to 24 h (Dollery, 1991b). 
The administration of cortrosyn was not associated with emesis in its own right and 
produced a clear inhibition of both the acute and delayed emetic response. The 
studies extend the findings of the clinic and further confirm the use of the ferret 
model as being capable of detecting the action of drugs to reduce emesis in man. 
Whilst the reduction of emesis was impressive, it is not known if the mechanism 
involves an activation of ACTH receptors to cause an increase in the endogenous 
synthesis and release of cortisol that would be expected to then mediate anti-emesis. 
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It would be necessary to repeat the experiment in animals pretreated with 
metyrapone. 
Cisplatin has been hypothesised to induced emesis via the generation of free radicals, 
that are inflammatory mediators, in Suncus murinus (Torii et al., 1994). There is 
evidence that ACTH (1-24) can reduce blood levels of free radicals induced by 
haemorrhagic-shock (Guarini et al., 1996). The mechanism was hypothesised to be 
adrenal-independent as it was mimicked by ACTH fragments that have negligible 
corticotropic activity and the effects were also seen in'adrenalectomised animals 
r 
(Guarini et al., 1996). It is not known, therefore, if such action contributes to the 
anti-emetic action of cortrosyn in the present studies. The experiments with 
cortrosyn in metyrapone treated animals may further clarify the situation. However, 
both cortrosyn and corticosteroids would be expected to reduce the levels of 
corticotrophin-releasing factor and vasopressin (Raff, 1987) and further studies on 
this potential mechanism are also required. 
4.5 Role of Cycloxygenase 
The possibility that postaglandins and thromboxane A2 could be involved in the 
development of delayed emesis was initially explored using indomethacin, a non-
selective cycloxygenase inhibitor (Carpenter et al., 1986). In the present studies, a 
wide dose-range was used but no anti-emetic action was seen. Indeed, delayed 
emesis was potentiated. Indomethacin has a potential to cause gastric ulceration 
(Mitchell & Warner，1999) but it is unknown if this side-effect contributed to the 
potentiation of delayed emesis and thus masked any potential anti-emetic benefit. 
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Therefore, it was decided to investigate the anti-emetic potential of two selective 
cycloxygenase-2 inhibitors. These agents have fewer gastric side-effects and do not 
cause gastric lesions in their own right (Mitchell & Warner, 1999). The compounds 
selected were DFU and L-745,337. 
DFU is a novel orally active and highly selective cycloxygenase-2 inhibitor. It has 
1,000 fold selectivity for cycloxygenase-2 over cycloxygenase-1 (Riendeau et al., 
1997). L-745,337 is also a relatively selective cycloxygenase-2 inhibitor and is 500 
to 1100 times more active to inhibit cycloxygenase-2 than cycloxygenase-1 (Chan et 
al, 1995; Giuliano & Warner/1999). The doses of DFU and L-745,337 used in the 
present studies do not induce gastric lesions in the rat (Chan et aL, 1995; Riendeau et 
al., 1997). 
Both drugs were difficult to formulate and were'supplied in limited amounts. The 
administration of the compounds was therefore timed to the glucocorticoid sensitive 
phase of the response, starting at 40 h. However, only DFU was capable of reducing 
emesis and the action was not long lasting and had a slow onset of action. L-745,337 
was ineffective but both drugs were used at doses that inhibit cycloxygenase-2 in 
inflammation (Riendeau et al, 1997; Turull & Queralt，2000). The lack of effect of 
L-745,337 and the fact that the action of DFU was not dose-related make it difficult 
to conclude with absolute certainty that cycloxygenase-2 plays a major role in the 
development of delayed emesis. Certainly, further experiments must be performed 
with other inhibitors to fully resolve the importance of cycloxygenase enzymes to 
control emesis. Further studies could be designed to measure the activity and levels 
of cycloxygenase-2 during the delayed phase. Generally, cycloxygenase-2 
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expression increases during inflammation (Davidson & Dennis, 1989) and it is of 
interest to determine if cisplatin can induce a similar increase. It would also be 
interesting to measure prostanoid levels during the delayed phase of emesis in 
conjunction with the experiments evaluating cycloxygenase function. 
Finally, it was noticeable that emesis was not potentiated with DFU and L-745,337. 
When the data is compared with indomethacin, it may be inferred that 
cycloxygenase-1 usually plays a protective role and that activation of prostanoid 
receptors may be useful to reduce emesis. However, this hypothesis must be viewed 
with caution since the administration of the two cycloxygenase-2 selective drugs was 
rather short. 
* 
4.6 Role of 5-Lipoxygenase 
5-Lipoxygenase is responsible for the biosynthesis of leukotrienes, which are also 
important inflammatory mediators. Glucocorticoids indirectly control the 
biosynthesis through inhibition of phospholipase A2 (see introduction). Leukotriene 
B4 levels are increased during Staphylococcus aureus challenge (Jett et al., 1990) and 
LY-171,883, a selective LTD4/LTE4 receptor antagonist inhibits emesis induced by 
staphylococcal enterotoxin B (SEB) to indicate that leukotrienes have emetic 
potential (Scheuber et al., 1987). MK-886, a specific 5-lipoxygenase activating 
protein (FLAP) inhibitor (Provost et al, 1998) was therefore selected to investigate 
the role of leukotrienes in the development of acute and delayed cisplatin-induced 
emesis. 
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In the present studies, there was a trend of MK-886 to inhibit cisplatin-induced 
emesis on day 3. This reduction suggests that 5-lipoxygenase is involved in 
antagonising cisplatin-induced emesis in the latter part of the delayed phase but 
further experiments to increase the group size of the animals are required to empower 
the data. It would also be desirable to use another 5-lipoxygenase inhibitor and 
direct lipoxygenase receptor antagonists to fully resolve the importance of 
leukotrienes to emesis control during the delayed phase. Certainly, the anti-emetic 
action of MK-886 can be considered inferior to cortrosyn and some of the 
corticosteroids used in the present studies. “ 
r 
4.7 Duel Inhibition of Cycloxygenase and 5-Lipoxygenase 
、 
At the start of the present research project, it w^s considered reasonable that the 
action of corticosteroids to reduce delayed emesis could be the result of decreasing 
the levels of arachidonic acid for metabolism to both prostanoids and leukotrienes. 
To further test this hypothesis, a combination of indomethacin and MK-886 was 
used. Both drugs were utilised at 10 mg/kg and as single treatments, were ineffective 
to significantly reduce emesis. However, the combination treatment potentiated 
emesis during the delayed phase and shortened the latency to onset of emesis. This 
result was unexpected. 
It is not known why the combination of indomethacin and MK-886 potentiated 
emesis. Is it possible that arachidonic acid was shunted to another pathway that 
produced a mediator that was emetic? Platelet activating factor (PAF) may be a 
potential candidate as infusion into piglets is known to cause emesis (Wechsung & 
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Houvenaghel, 1999). The role of hydroxyeicosatetraenoic acid (HETE) derivatives 
to emesis control is unknown. It may also be worthy of consideration that blocking 
cycloxygenase and 5-lipoxygenase fails to fully mimic the action of the 
corticosteroids, since the treatments do not have a modulatory role on the 
hypothalamic-pituitary-adrenal axis. In any event, the data suggests that the action 
of corticosteroids to antagonise emesis is dissociated from their known action to 
reduce the production of prostanoids and leukotrienes. However, the experiments 
should be repeated using combinations of cycloxygenase-2 selective inhibitors and 
MK-886 before making firm conclusions. ” 
产 
4,8 Anti-Emetic Potential of Glucocorticoids in Suncus murinus 
、 
A previous study in man reported the anti-emetic activity of dexamethasone to 
reduce motion sickness (see introduction). As motion is unlikely to involve 
inflammation, the results with dexamethasone indicate an anti-emetic action that is 
possibly independent of reducing the levels of inflammatory mediators. The motion-
induced emesis model may therefore provide a situation to further dissect the anti-
emetic action of corticosteroids that may be relevant to their general use as anti-
emetic drugs. • 
Suncus murinus has been used as a laboratory animal to study the mechanism(s) of 
motion-induced emesis for over 10 years (see introduction). In these studies, female 
Suncus murinus were more sensitive (in terms of the numbers of emetic episodes) 
than male animals and this is consistent with previous findings (Matsuki et al, 
1997); such sex differences also occur in man (Matsuki et al., 1997). 
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Unfortunately, the present studies were problematic to conduct as some of the control 
animals in the experiments failed to develop emesis. In the initial protocol, motion-
naive animals that were randomised to receive drug or vehicle treatment before being 
exposed to motion (Javid & Naylor, 1999). Thus, the protocol did not select the 
motion sensitive animals prior to the experiment. The data generated during the 
course of this thesis demonstrated that only 90.1 % of the vehicle control animals 
were sensitive to the motion stimulus. Presumably, therefore, each drug treatment 
group should also have a proportion (i.e. 9.9 %) of animals that are relatively 
insensitive to the motion stimulus. Such a situation is -not ideal and required a 
greater number of animals to evaluate drug action. 
A second and more time-consuming approach was also performed to confirm the 
action of any corticosteroid that appeared active in the initial testing protocol. The � 
second protocol was initially developed by Torii and co-workers (Torii et al., 1991b) 
and may be considered more sensitive to detect drug action since the procedure 
involves pre-selecting animals that vomit on exposure to motion. 
In the present studies, only dexamethasone antagonised motion-induced emesis. 
Moreover, the antagonism was only evident in female motion naive Suncus muhnus. 
It is not known why betamethasone and methylprednisolone were inactive in the 
initial test. However, the experiments with dexamethasone represent the first 
occasions where the author handled the species. Thus, in the subsequent 
experiments, the author gained more experience in handling the animals and the 
animals may have been subjected to less stress. This may be an important 
consideration to the action of dexamethasone to reduce emesis in the initial 
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experiments given the role of endogenous cortisol and ACTH in the response of an 
animal to stressful stimuli (Fulkerson & Jamieson，1982; Malarkey et al., 1995). 
Cortisol is the primary glucocorticoid in Suncus murinus (Schiml & Rissman, 1999), 
the ferret (Rosenthal et cd., 1993) and human (Rosenthal et al., 1993). In the present 
studies, the cortisol levels of some of the Suncus murinus samples were low and 
undetectable by the immunoassay kit. Conversely, some of the ACTH levels were 
too high and were out of the range of the radioimmunoassay. Unfortunately, the 
limited availability of serum from the small animals negated retesting of the samples 
and the data was lost. Nevertheless, the cortisol levels measured in the present 
studies were similar to the normal human cortisol levels (Frohman, 1996a). The 
cortisol levels are 3.7 times higher than levels measured in a previous study in female 
Suncus murinus (Schiml & Rissman, 1999). The difference may be due to different � 
collection time of the blood compared with Schimal & Rissman study. 
In the present studies, motion consistently induced increases in cortisol levels in the 
experiments involving betamethasone and methylprednisolone. However, such 
increases were not seen in the initial experiments with dexamethasone, although an 
increase was subsequently seen in the male motion-sensitive animals. It was an 
important observation that the motion-induced increases in cortisol levels could be 
antagonised by the glucocorticoids, to suggest the existence of glucocorticoid 
receptors in the species. Conversely, there was no consistent trend in these studies 
for motion to alter ACTH levels. However, the glucocorticoids failed to suppress or 
alter ACTH levels in motion treated or normal animals. It may be possible that the 
doses of glucocorticoids used in the present studies were not high enough to 
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modulate the negative feedback in Suncus murinus. The mechanism of the 
glucocorticoids to reduce the motion-induced increases in cortisol levels may operate 
independently of ACTH function in this species. 
In the motion-induced emesis experiments, there was no correlation between cortisol 
levels and the numbers of emetic episodes. However, there was a positive 
correlation between ACTH levels and emesis but this correlation was only seen in 
female animals. In the experiments, however, it is difficult to ascertain if the ACTH 
level is the key modulator of emesis or that the changes observed were a response to 
other factor(s) modulating the,hypothalamic-pituitary-adrenal axis. The unknown 
factor(s) may be more involved in the control of emesis. 
What are the other factors that may have an involvement with the modulation o f � 
ACTH and/or cortisol? As described in the introduction, cortisol is the final product 
in the hypothalamic-pituitary-adrenal axis. This thesis has focused on cortisol, 
ACTH, leukotrienes and prostanoids as possible modulators/products of the axis. In 
the axis, the cortisol level may be up regulated by other hormones including 
corticotrophin releasing factor. The distribution of corticotrophin-releasing factor is 
broad and has been seen in the gastrointestinal tract in enterochromaffin cells of the 
human colon, stomach and duodenum and on various immune cells (see review 
Schafer etal., 1997). 
There are patients with hypothalamic-pituitary-adrenal axis damage that have 
elevated levels of ACTH that experience vomiting (Geusau & Stingl, 1997). There 
are other studies showing that patients with head injury have elevated levels of 
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vasopressin and ACTH and that these patients experience vomiting (Sato et al., 
1982). Indeed, vasopressin and ACTH were also elevated during parabolic flight-
induced emesis in human (Kohl, 1987). 
Certainly, vasopressin is involved in motion-induced emesis, since blocking the 
action of vasopressin APVi-receptor agonists prevent the emetic response in animal 
models (see introduction) and the administration of glucocorticoids can reduce 
ACTH and vasopressin levels (Raff, 1987) which may be relevant to the action of 
dexamethasone to reduce emesis in man. However, in the present studies, ACTH 
levels were not increased by,motion in Suncus murinus and, in any event, the 
glucocorticoids did not affect ACTH levels. These differences in the mechanism(s) 
modulating ACTH and vasopressin levels may explain the discrepancies between the 
studies in Suncus murinus and other species (Coulter et al., 1996; Keller-Wood & � 
Bell, 1988; Setchell et al., 1975) including m a n . ‘ 
4.9 General Summary 
Cisplatin (5 mg/kg) induced acute and delayed emesis in the ferret that was 
antagonised by a range of corticosteroids. In particular, the corticosteroids were 
most active to reduce the emesis during the 24-56 h period following cisplatin 
administration. The rank order of inhibitory potency of the corticosteroids indicated 
an involvement of glucocorticoid receptors and that cisplatin may induce 
inflammation or the production of inflammatory mediators. The involvement of 
inflammation or inflammatory mediators may begin on the first day of treatment 
since dexamethasone was more active to reduce delayed emesis if the administration 
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was on the first day. This hypothesis seems reasonable since betamethasone was 
also active to reduce emesis on day 1 of the studies. In addition, the activity of 
fludrocortisone suggests that mineralocorticoids may be useful to reduced emesis 
occurring during the later stages of the delayed response. 
It was hypothesised that anti-emetic treatment with glucocorticoids may mimic the 
action of endogenous cortisol and that prevention of cortisol synthesis may 
exacerbate emesis during the delayed phase. However, metyrapone only potentiated 
emesis during the acute phase and reduced emesis during the delayed phase. It was 
not known if metyrapone interfered with the negative feedback mechanism that 
operates at the level of the hypothalamus and the anterior pituitary but the ACTH 
mimetic, cortrosyn, was clearly capable of reducing acute and delayed emesis. 
Further experiments are required to investigate if cortrosyn is anti-emetic in animals � 
treated with metyrapone. ‘ 
The role of prostaglandins and leukotrienes, as inflammatory mediators that may be 
involved in the development of cisplatin-induced emesis was indirectly assessed 
using cycloxygenase and lipoxygenase inhibitors. Indomethacin, a non-selective 
cycloxygenase inhibitor, potentiated acute and delayed emesis. In contrast, the 
selective cycloxygenase-2 inhibitor, DFU, reduced delayed emesis. It is possible that 
cycloxygenase-1 normally produces prostanoids that are protective and that 
cycloxygenase-2 produces prostanoids that may contribute to emesis. However, a 
second cycloxygenase-2 inhibitor was not anti-emetic and therefore further 
experiments must be performed to resolve the potential anti-emetic action of 
cycloxygenase-2 inhibitors. 
. 150 
MK886 was utilised as a selective lipoxygenase inhibitor but the drug failed to 
mimic the action of glucocorticoids. Moreover, the combination of MK-886 with 
indomethacin was also ineffective to mimic the action of the glucocorticoids and an 
unexpected potentiation of delayed emesis was observed. This suggests that 
glucocorticoids antagonise emesis via mechanisms distinct from, or in addition to, 
their known action to reduced prostanoids and leukotrienes levels. 
In Suncus murinus, evidence was obtained to suggest that motion has a potential to 
induce emesis and to increase cortisol level. However, the increase in cortisol level 
was independent of emesis and glucocorticoids were not particularly active anti-
emetic drugs. Evidence was also obtained to suggest an involvement of ACTH in 
motion-induced emesis but only in female Suncus murinus. None of the 
glucocorticoids were capable of decreasing ACTH or cortisol levels in n o r m a l � 
animals which contrasts their known action in' other species. Such a species 
difference may explain the failure of the present studies to replicate the findings in 
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